[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZBEpDtlW5Z_Von5UlbZ5xN9tiWBSHlIB9ZhZoN1e3kQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"AbbVie (prior sponsor, Abbott)",[4],223,false,0,45,141830,73,[13,16,19,22,24,27,29,31],{"name":14,"count":15},"Rheumatoid Arthritis",27,{"name":17,"count":18},"Secondary Hyperparathyroidism",11,{"name":20,"count":21},"Psoriasis",10,{"name":23,"count":21},"Chronic Hepatitis C Infection",{"name":25,"count":26},"Psoriatic Arthritis",8,{"name":28,"count":26},"Ankylosing Spondylitis",{"name":30,"count":26},"Crohn's Disease",{"name":32,"count":26},"Chronic Kidney Disease",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,131,191,227,255,423,470,518,571,605,655,699,721,751,781,805,831,849,867,885,920,938,956,980,998,1016,1034,1052,1077,1159,1236,1274,1312,1382,1436,1500,1556,1586,1624,1654,1683,1709,1748,1770,1801,1823,1861,1886,1915,1945,1967,1985,2009,2027,2050,2068,2093,2111,2129,2154,2172,2190,2208,2226,2244,2262,2280,2298,2324,2342,2360,2378,2396,2414,2432,2457,2475,2493,2517,2535,2558,2581,2599,2622,2640,2663,2681,2704,2722,2740,2762,2786,2804,2822,2845,2863,2881,2899,2917,2935,2959,2977,2995,3017,3055,3092,3122,3140,3163,3181,3205,3223,3241,3259,3281,3308,3326,3344,3368,3386,3404,3422,3440,3458,3476,3494,3683,3738,3756],{"intervention":43,"totalTrials":44,"cells":45},"Methotrexate",7,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":101,"NA":129},{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[],{"trials":53,"activeCount":8},[54,67,77,90],{"nctId":55,"briefTitle":56,"status":57,"phases":58,"primaryCompletion":59,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"NCT01251614","A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","COMPLETED",[38],"2013-12","2015-02","2010-12",114,[64],"Plaque Psoriasis",[66,43],"Adalimumab",{"nctId":68,"briefTitle":69,"status":57,"phases":70,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":75},"NCT00679731","A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis",[38],"2009-11","2008-04",317,[20],[76,43],"ABT-874",{"nctId":78,"briefTitle":79,"status":57,"phases":80,"primaryCompletion":81,"completion":82,"start":83,"enrollment":84,"conditions":85,"interventions":87},"NCT00195663","Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis",[38],"2004-04","2012-04","2000-12",799,[86],"Early Rheumatoid Arthritis",[66,43,88,89],"Adalimumab placebo","Methotrexate placebo",{"nctId":91,"briefTitle":92,"status":57,"phases":93,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT01185301","Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)",[38],"2012-09","2010-10",395,[86],[99,100],"adalimumab","methotrexate",{"trials":102,"activeCount":8},[103,112,121],{"nctId":104,"briefTitle":105,"status":57,"phases":106,"primaryCompletion":94,"completion":94,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT00808509","A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission",[39],"2009-01",33,[110],"Arthritis, Rheumatoid",[99,100],{"nctId":113,"briefTitle":114,"status":57,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT01185288","A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)",[39],"2013-01","2010-09",309,[14],[66,43],{"nctId":122,"briefTitle":123,"status":57,"phases":124,"primaryCompletion":125,"completion":125,"start":117,"enrollment":126,"conditions":127,"interventions":128},"NCT01162421","A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis",[39],"2015-07",77,[14],[99,43],{"trials":130,"activeCount":8},[],{"intervention":132,"totalTrials":133,"cells":134},"Levodopa-carbidopa intestinal gel",4,{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":177,"NA":189},{"trials":136,"activeCount":8},[],{"trials":138,"activeCount":8},[],{"trials":140,"activeCount":8},[],{"trials":142,"activeCount":8},[143,153,165],{"nctId":144,"briefTitle":145,"status":57,"phases":146,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":152},"NCT00335153","Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease",[38],"2012-06","2008-01",354,[151],"Advanced Parkinson's Disease",[132],{"nctId":154,"briefTitle":155,"status":57,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT01736176","A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease",[38],"2015-03","2015-12","2013-03",39,[151],[163,164],"Levodopa-Carbidopa Intestinal Gel","Levodopa-carbidopa Immediate Release (LC-IR)",{"nctId":166,"briefTitle":167,"status":57,"phases":168,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":176},"NCT00360568","Safety\u002FEfficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects",[38],"2012-10","2009-06",62,[173,174,175],"Dyskinesias","Parkinson's Disease","Severe Motor Fluctuations",[132],{"trials":178,"activeCount":8},[179],{"nctId":180,"briefTitle":181,"status":57,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":126,"conditions":186,"interventions":188},"NCT00141518","Long-term Study of Duodopa (Levodopa\u002FCarbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact",[39],"2011-03","2011-04","2006-03",[187],"Advanced Idiopathic Parkinson's Disease",[132],{"trials":190,"activeCount":8},[],{"intervention":192,"totalTrials":193,"cells":194},"Lopinavir\u002FRitonavir",2,{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":225},{"trials":196,"activeCount":8},[],{"trials":198,"activeCount":8},[],{"trials":200,"activeCount":8},[],{"trials":202,"activeCount":8},[],{"trials":204,"activeCount":8},[205,214],{"nctId":206,"briefTitle":207,"status":57,"phases":208,"primaryCompletion":148,"completion":148,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT00234975","Safety of Lopinavir\u002FRitonavir (Kaletra) in HIV\u002FHCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score",[39],"2002-10",86,[212],"HIV Infection",[192],{"nctId":215,"briefTitle":216,"status":57,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT00648999","Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients",[39],"2006-12","2003-11",207,[222],"Human Immunodeficiency Virus",[224],"lopinavir\u002Fritonavir",{"trials":226,"activeCount":8},[],{"intervention":228,"totalTrials":229,"cells":230},"Darbepoetin alfa",1,{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":253},{"trials":232,"activeCount":8},[],{"trials":234,"activeCount":8},[],{"trials":236,"activeCount":8},[],{"trials":238,"activeCount":8},[],{"trials":240,"activeCount":8},[241],{"nctId":242,"briefTitle":243,"status":57,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":251},"NCT01506947","A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients",[39],"2016-04-07","2012-05-10",65,[249,250],"Moderate to Severe Secondary Hyperparathyroidism","Stage 5 Chronic Kidney Diseases",[252,228],"Paricalcitol",{"trials":254,"activeCount":8},[],{"intervention":256,"totalTrials":257,"cells":258},"Ribavirin",15,{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":373,"PHASE4":419,"NA":421},{"trials":260,"activeCount":8},[],{"trials":262,"activeCount":8},[],{"trials":264,"activeCount":8},[265,279,291,308,318,328,337,346,356,366],{"nctId":266,"briefTitle":267,"status":57,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT01458535","A Study to Evaluate Paritaprevir With Ritonavir (ABT-450\u002Fr) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)",[37],"2013-05","2011-09",61,[273],"Hepatitis C Virus",[275,276,277,278],"ABT-450","ABT-267","ribavirin","ritonavir",{"nctId":280,"briefTitle":281,"status":57,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT01609933","A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie\u002FAbbott Combination Study",[37],"2017-05-03","2012-12-18",32,[287],"Chronic Hepatitis C",[289,276,290,256],"ABT-450\u002Fr","pegylated interferon alpha-2a",{"nctId":292,"briefTitle":293,"status":57,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":303},"NCT01074008","A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072",[37],"2011-06","2012-01","2010-03",74,[300,301,23,302],"Hepatitis C","HCV","Hepatitis C Genotype 1",[275,304,305,306,307,256],"ABT-072","ABT-333","Ritonavir","Peginterferon alpha-2a",{"nctId":309,"briefTitle":310,"status":57,"phases":311,"primaryCompletion":312,"completion":60,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT01685203","A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450\u002Fr) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection",[37],"2014-06","2012-08",316,[316],"Hepatitis C, Chronic",[289,276,256],{"nctId":319,"briefTitle":320,"status":57,"phases":321,"primaryCompletion":296,"completion":322,"start":183,"enrollment":323,"conditions":324,"interventions":326},"NCT01314261","Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects",[37],"2013-02",37,[287,325],"Hepatitis C Virus (HCV) Infection",[276,327,256],"Pegylated interferon",{"nctId":329,"briefTitle":330,"status":57,"phases":331,"primaryCompletion":82,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT01563536","Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects",[37],"2013-06","2012-02",12,[23],[276,275,305,306,256],{"nctId":338,"briefTitle":339,"status":57,"phases":340,"primaryCompletion":341,"completion":169,"start":342,"enrollment":343,"conditions":344,"interventions":345},"NCT01306617","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450\u002Fr) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",[37],"2011-11","2011-02",50,[23,300,273],[275,305,277,278],{"nctId":347,"briefTitle":348,"status":57,"phases":349,"primaryCompletion":159,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},"NCT01464827","ABT-450 With Ritonavir and ABT-267 and\u002For ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients",[37],"2013-09","2011-10",580,[287,354,302],"Hepatitis C (HCV)",[275,305,276,256,306],{"nctId":357,"briefTitle":358,"status":57,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":365},"NCT00851890","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",[37],"2009-07","2009-03",30,[364],"Chronic Hepatitis C Virus Infection",[305,327,256],{"nctId":367,"briefTitle":368,"status":57,"phases":369,"primaryCompletion":370,"completion":82,"start":95,"enrollment":18,"conditions":371,"interventions":372},"NCT01221298","A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450\u002Fr) Dosed in Combination With ABT-072 and Ribavirin (RBV)",[37],"2011-05",[300,301,23,302],[275,304,256,306],{"trials":374,"activeCount":8},[375,385,393,402,411],{"nctId":376,"briefTitle":377,"status":57,"phases":378,"primaryCompletion":379,"completion":380,"start":313,"enrollment":381,"conditions":382,"interventions":383},"NCT01674725","A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450\u002FRitonavir\u002FABT-267 (ABT-450\u002Fr\u002FABT-267) and ABT-333 in Subjects With Chronic Hepatitis C",[38],"2014-01","2014-10",187,[23],[384,256],"ABT-450\u002Fr\u002FABT-267, ABT-333",{"nctId":386,"briefTitle":387,"status":57,"phases":388,"primaryCompletion":389,"completion":380,"start":390,"enrollment":96,"conditions":391,"interventions":392},"NCT01715415","A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults",[38],"2013-11","2012-11",[23],[384,256],{"nctId":394,"briefTitle":395,"status":57,"phases":396,"primaryCompletion":379,"completion":397,"start":169,"enrollment":398,"conditions":399,"interventions":401},"NCT01704755","A Study to Evaluate the Safety and Efficacy of ABT-450\u002FRitonavir\u002FABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis",[38],"2014-09",381,[23,400],"Compensated Cirrhosis",[384,256],{"nctId":403,"briefTitle":404,"status":57,"phases":405,"primaryCompletion":59,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT01767116","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection",[38],"2014-08","2012-12",419,[23],[384,256],{"nctId":412,"briefTitle":413,"status":57,"phases":414,"primaryCompletion":415,"completion":380,"start":390,"enrollment":416,"conditions":417,"interventions":418},"NCT01716585","A Study to Evaluate Chronic Hepatitis C Infection",[38],"2013-10",636,[23],[384,256],{"trials":420,"activeCount":8},[],{"trials":422,"activeCount":8},[],{"intervention":276,"totalTrials":44,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":455,"PHASE4":466,"NA":468},{"trials":426,"activeCount":8},[],{"trials":428,"activeCount":8},[],{"trials":430,"activeCount":8},[431,435,439,443,447,451],{"nctId":266,"briefTitle":267,"status":57,"phases":432,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":433,"interventions":434},[37],[273],[275,276,277,278],{"nctId":280,"briefTitle":281,"status":57,"phases":436,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":437,"interventions":438},[37],[287],[289,276,290,256],{"nctId":309,"briefTitle":310,"status":57,"phases":440,"primaryCompletion":312,"completion":60,"start":313,"enrollment":314,"conditions":441,"interventions":442},[37],[316],[289,276,256],{"nctId":319,"briefTitle":320,"status":57,"phases":444,"primaryCompletion":296,"completion":322,"start":183,"enrollment":323,"conditions":445,"interventions":446},[37],[287,325],[276,327,256],{"nctId":329,"briefTitle":330,"status":57,"phases":448,"primaryCompletion":82,"completion":332,"start":333,"enrollment":334,"conditions":449,"interventions":450},[37],[23],[276,275,305,306,256],{"nctId":347,"briefTitle":348,"status":57,"phases":452,"primaryCompletion":159,"completion":350,"start":351,"enrollment":352,"conditions":453,"interventions":454},[37],[287,354,302],[275,305,276,256,306],{"trials":456,"activeCount":8},[457],{"nctId":458,"briefTitle":459,"status":57,"phases":460,"primaryCompletion":461,"completion":461,"start":332,"enrollment":462,"conditions":463,"interventions":464},"NCT01773070","A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study",[38],"2016-10",478,[300],[465,305,276],"ABT-450\u002Fritonavir",{"trials":467,"activeCount":8},[],{"trials":469,"activeCount":8},[],{"intervention":305,"totalTrials":44,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":508,"PHASE4":514,"NA":516},{"trials":473,"activeCount":8},[],{"trials":475,"activeCount":8},[],{"trials":477,"activeCount":8},[478,482,486,490,494,504],{"nctId":292,"briefTitle":293,"status":57,"phases":479,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":480,"interventions":481},[37],[300,301,23,302],[275,304,305,306,307,256],{"nctId":329,"briefTitle":330,"status":57,"phases":483,"primaryCompletion":82,"completion":332,"start":333,"enrollment":334,"conditions":484,"interventions":485},[37],[23],[276,275,305,306,256],{"nctId":338,"briefTitle":339,"status":57,"phases":487,"primaryCompletion":341,"completion":169,"start":342,"enrollment":343,"conditions":488,"interventions":489},[37],[23,300,273],[275,305,277,278],{"nctId":347,"briefTitle":348,"status":57,"phases":491,"primaryCompletion":159,"completion":350,"start":351,"enrollment":352,"conditions":492,"interventions":493},[37],[287,354,302],[275,305,276,256,306],{"nctId":495,"briefTitle":496,"status":57,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":503},"NCT00726882","A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies",[37],"2010-05","2008-08",35,[502],"HCV Infection",[305],{"nctId":357,"briefTitle":358,"status":57,"phases":505,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":506,"interventions":507},[37],[364],[305,327,256],{"trials":509,"activeCount":8},[510],{"nctId":458,"briefTitle":459,"status":57,"phases":511,"primaryCompletion":461,"completion":461,"start":332,"enrollment":462,"conditions":512,"interventions":513},[38],[300],[465,305,276],{"trials":515,"activeCount":8},[],{"trials":517,"activeCount":8},[],{"intervention":76,"totalTrials":519,"cells":520},5,{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":567,"NA":569},{"trials":522,"activeCount":8},[],{"trials":524,"activeCount":8},[],{"trials":526,"activeCount":8},[],{"trials":528,"activeCount":8},[529,538,547,551,559],{"nctId":530,"briefTitle":531,"status":57,"phases":532,"primaryCompletion":351,"completion":351,"start":533,"enrollment":534,"conditions":535,"interventions":537},"NCT00626002","Open Label Continuation Study in Moderate to Severe Psoriasis",[38],"2008-02",2301,[536],"Moderate to Severe Plaque Psoriasis",[76],{"nctId":539,"briefTitle":540,"status":57,"phases":541,"primaryCompletion":361,"completion":361,"start":542,"enrollment":543,"conditions":544,"interventions":545},"NCT00691964","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[38],"2008-05",347,[64],[76,546],"etanercept",{"nctId":68,"briefTitle":69,"status":57,"phases":548,"primaryCompletion":71,"completion":71,"start":72,"enrollment":73,"conditions":549,"interventions":550},[38],[20],[76,43],{"nctId":552,"briefTitle":540,"status":57,"phases":553,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":558},"NCT00710580",[38],"2009-04","2008-07",350,[536],[76,546],{"nctId":560,"briefTitle":561,"status":57,"phases":562,"primaryCompletion":170,"completion":170,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT00570986","A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[38],"2007-11",1465,[64],[76,76],{"trials":568,"activeCount":8},[],{"trials":570,"activeCount":8},[],{"intervention":384,"totalTrials":519,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":601,"NA":603},{"trials":574,"activeCount":8},[],{"trials":576,"activeCount":8},[],{"trials":578,"activeCount":8},[],{"trials":580,"activeCount":8},[581,585,589,593,597],{"nctId":376,"briefTitle":377,"status":57,"phases":582,"primaryCompletion":379,"completion":380,"start":313,"enrollment":381,"conditions":583,"interventions":584},[38],[23],[384,256],{"nctId":386,"briefTitle":387,"status":57,"phases":586,"primaryCompletion":389,"completion":380,"start":390,"enrollment":96,"conditions":587,"interventions":588},[38],[23],[384,256],{"nctId":394,"briefTitle":395,"status":57,"phases":590,"primaryCompletion":379,"completion":397,"start":169,"enrollment":398,"conditions":591,"interventions":592},[38],[23,400],[384,256],{"nctId":403,"briefTitle":404,"status":57,"phases":594,"primaryCompletion":59,"completion":406,"start":407,"enrollment":408,"conditions":595,"interventions":596},[38],[23],[384,256],{"nctId":412,"briefTitle":413,"status":57,"phases":598,"primaryCompletion":415,"completion":380,"start":390,"enrollment":416,"conditions":599,"interventions":600},[38],[23],[384,256],{"trials":602,"activeCount":8},[],{"trials":604,"activeCount":8},[],{"intervention":606,"totalTrials":607,"cells":608},"Elagolix",3,{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":622,"PHASE3":638,"PHASE4":651,"NA":653},{"trials":610,"activeCount":8},[],{"trials":612,"activeCount":8},[613],{"nctId":614,"briefTitle":615,"status":57,"phases":616,"primaryCompletion":169,"completion":390,"start":295,"enrollment":617,"conditions":618,"interventions":620},"NCT01403038","An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females",[36],216,[619],"Folliculogenesis",[606,606,606,606,606,606,621],"elagolix",{"trials":623,"activeCount":8},[624],{"nctId":625,"briefTitle":626,"status":57,"phases":627,"primaryCompletion":389,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":634},"NCT01441635","Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids",[37],"2014-05-17","2011-09-08",271,[632,633],"Heavy Uterine Bleeding","Uterine Fibroids",[606,635,636,637],"Estradiol\u002FNorethindrone acetate","Estradiol","Progesterone",{"trials":639,"activeCount":8},[640],{"nctId":641,"briefTitle":642,"status":57,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT01620528","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain",[38],"2014-11-14","2015-09-28","2012-05-22",872,[649],"Endometriosis",[621],{"trials":652,"activeCount":8},[],{"trials":654,"activeCount":8},[],{"intervention":656,"totalTrials":607,"cells":657},"Prednisone",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":695,"NA":697},{"trials":659,"activeCount":8},[],{"trials":661,"activeCount":8},[],{"trials":663,"activeCount":8},[],{"trials":665,"activeCount":8},[666,676,687],{"nctId":667,"briefTitle":668,"status":57,"phases":669,"primaryCompletion":670,"completion":406,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT01138657","Efficacy and Safety of Adalimumab in Patients With Active Uveitis",[38],"2014-07","2010-08",239,[674],"Uveitis",[66,656],{"nctId":677,"briefTitle":678,"status":57,"phases":679,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":685},"NCT01235689","Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease",[38],"2016-11-03","2017-01-03","2011-02-11",252,[30],[66,656,686],"Azathioprine",{"nctId":688,"briefTitle":689,"status":57,"phases":690,"primaryCompletion":691,"completion":691,"start":671,"enrollment":692,"conditions":693,"interventions":694},"NCT01124838","Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis",[38],"2015-05",261,[674],[66,656],{"trials":696,"activeCount":8},[],{"trials":698,"activeCount":8},[],{"intervention":546,"totalTrials":193,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":717,"NA":719},{"trials":702,"activeCount":8},[],{"trials":704,"activeCount":8},[],{"trials":706,"activeCount":8},[],{"trials":708,"activeCount":8},[709,713],{"nctId":539,"briefTitle":540,"status":57,"phases":710,"primaryCompletion":361,"completion":361,"start":542,"enrollment":543,"conditions":711,"interventions":712},[38],[64],[76,546],{"nctId":552,"briefTitle":540,"status":57,"phases":714,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":715,"interventions":716},[38],[536],[76,546],{"trials":718,"activeCount":8},[],{"trials":720,"activeCount":8},[],{"intervention":722,"totalTrials":193,"cells":723},"ABT-712",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":747,"NA":749},{"trials":725,"activeCount":8},[],{"trials":727,"activeCount":8},[],{"trials":729,"activeCount":8},[],{"trials":731,"activeCount":8},[732,741],{"nctId":733,"briefTitle":734,"status":57,"phases":735,"primaryCompletion":554,"completion":554,"start":736,"enrollment":737,"conditions":738,"interventions":740},"NCT00763321","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)",[38],"2008-09",287,[739],"Chronic Low Back Pain",[722],{"nctId":742,"briefTitle":734,"status":57,"phases":743,"primaryCompletion":361,"completion":361,"start":736,"enrollment":744,"conditions":745,"interventions":746},"NCT00761150",[38],308,[739],[722],{"trials":748,"activeCount":8},[],{"trials":750,"activeCount":8},[],{"intervention":752,"totalTrials":193,"cells":753},"Levodopa carbidopa intestinal gel",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":777,"NA":779},{"trials":755,"activeCount":8},[],{"trials":757,"activeCount":8},[],{"trials":759,"activeCount":8},[],{"trials":761,"activeCount":8},[762,770],{"nctId":763,"briefTitle":764,"status":57,"phases":765,"primaryCompletion":351,"completion":351,"start":107,"enrollment":766,"conditions":767,"interventions":768},"NCT00357994","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",[38],36,[151],[752,769],"Levodopa carbidopa (LC) oral encapsulated immediate release (IR)",{"nctId":771,"briefTitle":764,"status":57,"phases":772,"primaryCompletion":351,"completion":351,"start":773,"enrollment":500,"conditions":774,"interventions":775},"NCT00660387",[38],"2009-12",[151],[752,776],"Levodopa-carbidopa (LC) oral encapsulated immediate release (IR)",{"trials":778,"activeCount":8},[],{"trials":780,"activeCount":8},[],{"intervention":782,"totalTrials":229,"cells":783},"Palivizumab",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":801,"NA":803},{"trials":785,"activeCount":8},[],{"trials":787,"activeCount":8},[],{"trials":789,"activeCount":8},[],{"trials":791,"activeCount":8},[792],{"nctId":793,"briefTitle":794,"status":57,"phases":795,"primaryCompletion":82,"completion":82,"start":796,"enrollment":797,"conditions":798,"interventions":800},"NCT01466062","Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions",[38],"2011-08",28,[799],"Respiratory Syncytial Virus Infection",[782],{"trials":802,"activeCount":8},[],{"trials":804,"activeCount":8},[],{"intervention":806,"totalTrials":229,"cells":807},"maxacalcitol",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":827,"NA":829},{"trials":809,"activeCount":8},[],{"trials":811,"activeCount":8},[],{"trials":813,"activeCount":8},[],{"trials":815,"activeCount":8},[816],{"nctId":817,"briefTitle":818,"status":57,"phases":819,"primaryCompletion":82,"completion":82,"start":370,"enrollment":820,"conditions":821,"interventions":823},"NCT01341782","Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism",[38],255,[17,822],"Hemodialysis",[824,806,825,826],"paricalcitol","paricalcitol placebo","maxacalcitol placebo",{"trials":828,"activeCount":8},[],{"trials":830,"activeCount":8},[],{"intervention":825,"totalTrials":229,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":845,"NA":847},{"trials":834,"activeCount":8},[],{"trials":836,"activeCount":8},[],{"trials":838,"activeCount":8},[],{"trials":840,"activeCount":8},[841],{"nctId":817,"briefTitle":818,"status":57,"phases":842,"primaryCompletion":82,"completion":82,"start":370,"enrollment":820,"conditions":843,"interventions":844},[38],[17,822],[824,806,825,826],{"trials":846,"activeCount":8},[],{"trials":848,"activeCount":8},[],{"intervention":826,"totalTrials":229,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":863,"NA":865},{"trials":852,"activeCount":8},[],{"trials":854,"activeCount":8},[],{"trials":856,"activeCount":8},[],{"trials":858,"activeCount":8},[859],{"nctId":817,"briefTitle":818,"status":57,"phases":860,"primaryCompletion":82,"completion":82,"start":370,"enrollment":820,"conditions":861,"interventions":862},[38],[17,822],[824,806,825,826],{"trials":864,"activeCount":8},[],{"trials":866,"activeCount":8},[],{"intervention":465,"totalTrials":229,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":881,"NA":883},{"trials":870,"activeCount":8},[],{"trials":872,"activeCount":8},[],{"trials":874,"activeCount":8},[],{"trials":876,"activeCount":8},[877],{"nctId":458,"briefTitle":459,"status":57,"phases":878,"primaryCompletion":461,"completion":461,"start":332,"enrollment":462,"conditions":879,"interventions":880},[38],[300],[465,305,276],{"trials":882,"activeCount":8},[],{"trials":884,"activeCount":8},[],{"intervention":886,"totalTrials":229,"cells":887},"Leuprolide Acetate 3 Month Depot",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":916,"NA":918},{"trials":889,"activeCount":8},[],{"trials":891,"activeCount":8},[],{"trials":893,"activeCount":8},[],{"trials":895,"activeCount":8},[896],{"nctId":897,"briefTitle":898,"status":57,"phases":899,"primaryCompletion":169,"completion":116,"start":900,"enrollment":901,"conditions":902,"interventions":915},"NCT00667446","Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty",[38],"2008-12",72,[903,904,905,906,907,908,909,910,911,912,913,914],"Precocious","Leuprolide Acetate","Luteinizing Hormone (LH)","Gonadotrophin-releasing Hormone Agonist (GnRHa)","Tanner Staging","Depot Formulation","Suppression of LH","Central Precocious Puberty (CPP)","Gonadotrophin-releasing Hormone (GnRH)","Lupron","GnRH Analog","Pediatrics Central Precocious Puberty",[886],{"trials":917,"activeCount":8},[],{"trials":919,"activeCount":8},[],{"intervention":769,"totalTrials":229,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":934,"NA":936},{"trials":923,"activeCount":8},[],{"trials":925,"activeCount":8},[],{"trials":927,"activeCount":8},[],{"trials":929,"activeCount":8},[930],{"nctId":763,"briefTitle":764,"status":57,"phases":931,"primaryCompletion":351,"completion":351,"start":107,"enrollment":766,"conditions":932,"interventions":933},[38],[151],[752,769],{"trials":935,"activeCount":8},[],{"trials":937,"activeCount":8},[],{"intervention":686,"totalTrials":229,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":952,"NA":954},{"trials":941,"activeCount":8},[],{"trials":943,"activeCount":8},[],{"trials":945,"activeCount":8},[],{"trials":947,"activeCount":8},[948],{"nctId":677,"briefTitle":678,"status":57,"phases":949,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":950,"interventions":951},[38],[30],[66,656,686],{"trials":953,"activeCount":8},[],{"trials":955,"activeCount":8},[],{"intervention":957,"totalTrials":229,"cells":958},"Open-label Adalimumab",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":976,"NA":978},{"trials":960,"activeCount":8},[],{"trials":962,"activeCount":8},[],{"trials":964,"activeCount":8},[],{"trials":966,"activeCount":8},[967],{"nctId":968,"briefTitle":969,"status":57,"phases":970,"primaryCompletion":342,"completion":971,"start":360,"enrollment":972,"conditions":973,"interventions":975},"NCT00939003","Study of Adalimumab in Patients With Axial Spondyloarthritis",[38],"2013-08",192,[974],"Axial Spondyloarthritis",[66,957],{"trials":977,"activeCount":8},[],{"trials":979,"activeCount":8},[],{"intervention":88,"totalTrials":229,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":994,"NA":996},{"trials":983,"activeCount":8},[],{"trials":985,"activeCount":8},[],{"trials":987,"activeCount":8},[],{"trials":989,"activeCount":8},[990],{"nctId":78,"briefTitle":79,"status":57,"phases":991,"primaryCompletion":81,"completion":82,"start":83,"enrollment":84,"conditions":992,"interventions":993},[38],[86],[66,43,88,89],{"trials":995,"activeCount":8},[],{"trials":997,"activeCount":8},[],{"intervention":89,"totalTrials":229,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1012,"NA":1014},{"trials":1001,"activeCount":8},[],{"trials":1003,"activeCount":8},[],{"trials":1005,"activeCount":8},[],{"trials":1007,"activeCount":8},[1008],{"nctId":78,"briefTitle":79,"status":57,"phases":1009,"primaryCompletion":81,"completion":82,"start":83,"enrollment":84,"conditions":1010,"interventions":1011},[38],[86],[66,43,88,89],{"trials":1013,"activeCount":8},[],{"trials":1015,"activeCount":8},[],{"intervention":164,"totalTrials":229,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":8},[],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[],{"trials":1025,"activeCount":8},[1026],{"nctId":154,"briefTitle":155,"status":57,"phases":1027,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":1028,"interventions":1029},[38],[151],[163,164],{"trials":1031,"activeCount":8},[],{"trials":1033,"activeCount":8},[],{"intervention":776,"totalTrials":229,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":8},[],{"trials":1039,"activeCount":8},[],{"trials":1041,"activeCount":8},[],{"trials":1043,"activeCount":8},[1044],{"nctId":771,"briefTitle":764,"status":57,"phases":1045,"primaryCompletion":351,"completion":351,"start":773,"enrollment":500,"conditions":1046,"interventions":1047},[38],[151],[752,776],{"trials":1049,"activeCount":8},[],{"trials":1051,"activeCount":8},[],{"intervention":1053,"totalTrials":229,"cells":1054},"ABT-335",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1073,"NA":1075},{"trials":1056,"activeCount":8},[],{"trials":1058,"activeCount":8},[],{"trials":1060,"activeCount":8},[],{"trials":1062,"activeCount":8},[1063],{"nctId":1064,"briefTitle":1065,"status":57,"phases":1066,"primaryCompletion":94,"completion":94,"start":533,"enrollment":1067,"conditions":1068,"interventions":1072},"NCT00616772","Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",[38],682,[1069,1070,1071],"Coronary Artery Disease","Coronary Heart Disease","Dyslipidemia",[1053],{"trials":1074,"activeCount":8},[],{"trials":1076,"activeCount":8},[],{"intervention":1078,"totalTrials":26,"cells":1079},"ABT-126",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1081,"activeCount":8},[],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[1086,1096,1104,1114,1121,1129,1137,1146],{"nctId":1087,"briefTitle":1088,"status":1089,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":313,"enrollment":1092,"conditions":1093,"interventions":1095},"NCT01676935","This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease","TERMINATED",[37],"2014-03",349,[1094],"Alzheimer's Disease",[1078],{"nctId":1097,"briefTitle":1098,"status":57,"phases":1099,"primaryCompletion":415,"completion":415,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT01549834","Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",[37],"2012-03",434,[1094],[1078,1078],{"nctId":1105,"briefTitle":1106,"status":57,"phases":1107,"primaryCompletion":1108,"completion":670,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1113},"NCT01655680","A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia",[37],"2014-04","2012-05",432,[1112],"Schizophrenia",[1078,1078,1078],{"nctId":1115,"briefTitle":1116,"status":57,"phases":1117,"primaryCompletion":796,"completion":270,"start":297,"enrollment":220,"conditions":1118,"interventions":1120},"NCT01095562","Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia",[37],[1119],"Cognitive Deficits in Schizophrenia",[1078],{"nctId":1122,"briefTitle":1123,"status":57,"phases":1124,"primaryCompletion":389,"completion":389,"start":333,"enrollment":1125,"conditions":1126,"interventions":1127},"NCT01527916","Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",[37],438,[1094],[1128,1078],"donepezil",{"nctId":1130,"briefTitle":1131,"status":1089,"phases":1132,"primaryCompletion":1133,"completion":1133,"start":94,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT01690195","Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease",[37],"2014-02",343,[1094],[1078],{"nctId":1138,"briefTitle":1139,"status":57,"phases":1140,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1145},"NCT00948909","Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease",[37],"2010-11","2009-10",274,[1094],[1078,1128],{"nctId":1147,"briefTitle":1148,"status":57,"phases":1149,"primaryCompletion":1091,"completion":1091,"start":313,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT01678755","A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia",[37],157,[1112],[1078,1078],{"trials":1154,"activeCount":8},[],{"trials":1156,"activeCount":8},[],{"trials":1158,"activeCount":8},[],{"intervention":1160,"totalTrials":1161,"cells":1162},"ABT-869",6,{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1176,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1164,"activeCount":8},[],{"trials":1166,"activeCount":8},[1167],{"nctId":1168,"briefTitle":1169,"status":57,"phases":1170,"primaryCompletion":147,"completion":147,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT00733187","Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869",[36],"2009-02",34,[1174],"Advanced Solid Tumors",[1160],{"trials":1177,"activeCount":8},[1178,1187,1202,1211,1219],{"nctId":1179,"briefTitle":1180,"status":57,"phases":1181,"primaryCompletion":295,"completion":147,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1186},"NCT00517920","Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)",[37],"2007-09",44,[1185],"Advanced Hepatocellular Carcinoma",[1160],{"nctId":1188,"briefTitle":1189,"status":57,"phases":1190,"primaryCompletion":1109,"completion":1109,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1197},"NCT00707889","Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer",[37],"2008-10",159,[1194,1195,1196],"Advanced Colorectal Cancer","Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum",[1160,1198,1199,1200,1201,1160],"bevacizumab","oxaliplatin","folinic acid","fluorouracil",{"nctId":1203,"briefTitle":1204,"status":57,"phases":1205,"primaryCompletion":295,"completion":147,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1210},"NCT00486538","Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib",[37],"2007-06",53,[1209],"Advanced Renal Cell Carcinoma",[1160],{"nctId":1212,"briefTitle":1213,"status":57,"phases":1214,"primaryCompletion":773,"completion":773,"start":555,"enrollment":21,"conditions":1215,"interventions":1217},"NCT00645177","Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer",[37],[1216],"Metastatic Breast Cancer",[1160,1218],"paclitaxel",{"nctId":1220,"briefTitle":1221,"status":57,"phases":1222,"primaryCompletion":82,"completion":82,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1227},"NCT00716534","Study of Carboplatin\u002FPaclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[37],"2008-06",145,[1226],"Advanced or Metastatic Non-Small Cell Lung Cancer",[1160,1160,1228,1229],"Carboplatin","Paclitaxel",{"trials":1231,"activeCount":8},[],{"trials":1233,"activeCount":8},[],{"trials":1235,"activeCount":8},[],{"intervention":275,"totalTrials":1161,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1239,"activeCount":8},[],{"trials":1241,"activeCount":8},[],{"trials":1243,"activeCount":8},[1244,1248,1252,1256,1260,1264],{"nctId":266,"briefTitle":267,"status":57,"phases":1245,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":1246,"interventions":1247},[37],[273],[275,276,277,278],{"nctId":292,"briefTitle":293,"status":57,"phases":1249,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":1250,"interventions":1251},[37],[300,301,23,302],[275,304,305,306,307,256],{"nctId":329,"briefTitle":330,"status":57,"phases":1253,"primaryCompletion":82,"completion":332,"start":333,"enrollment":334,"conditions":1254,"interventions":1255},[37],[23],[276,275,305,306,256],{"nctId":338,"briefTitle":339,"status":57,"phases":1257,"primaryCompletion":341,"completion":169,"start":342,"enrollment":343,"conditions":1258,"interventions":1259},[37],[23,300,273],[275,305,277,278],{"nctId":347,"briefTitle":348,"status":57,"phases":1261,"primaryCompletion":159,"completion":350,"start":351,"enrollment":352,"conditions":1262,"interventions":1263},[37],[287,354,302],[275,305,276,256,306],{"nctId":367,"briefTitle":368,"status":57,"phases":1265,"primaryCompletion":370,"completion":82,"start":95,"enrollment":18,"conditions":1266,"interventions":1267},[37],[300,301,23,302],[275,304,256,306],{"trials":1269,"activeCount":8},[],{"trials":1271,"activeCount":8},[],{"trials":1273,"activeCount":8},[],{"intervention":306,"totalTrials":1161,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1277,"activeCount":8},[],{"trials":1279,"activeCount":8},[],{"trials":1281,"activeCount":8},[1282,1286,1290,1294,1298,1302],{"nctId":266,"briefTitle":267,"status":57,"phases":1283,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":1284,"interventions":1285},[37],[273],[275,276,277,278],{"nctId":292,"briefTitle":293,"status":57,"phases":1287,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":1288,"interventions":1289},[37],[300,301,23,302],[275,304,305,306,307,256],{"nctId":329,"briefTitle":330,"status":57,"phases":1291,"primaryCompletion":82,"completion":332,"start":333,"enrollment":334,"conditions":1292,"interventions":1293},[37],[23],[276,275,305,306,256],{"nctId":338,"briefTitle":339,"status":57,"phases":1295,"primaryCompletion":341,"completion":169,"start":342,"enrollment":343,"conditions":1296,"interventions":1297},[37],[23,300,273],[275,305,277,278],{"nctId":347,"briefTitle":348,"status":57,"phases":1299,"primaryCompletion":159,"completion":350,"start":351,"enrollment":352,"conditions":1300,"interventions":1301},[37],[287,354,302],[275,305,276,256,306],{"nctId":367,"briefTitle":368,"status":57,"phases":1303,"primaryCompletion":370,"completion":82,"start":95,"enrollment":18,"conditions":1304,"interventions":1305},[37],[300,301,23,302],[275,304,256,306],{"trials":1307,"activeCount":8},[],{"trials":1309,"activeCount":8},[],{"trials":1311,"activeCount":8},[],{"intervention":1313,"totalTrials":1161,"cells":1314},"Veliparib",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1356,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1316,"activeCount":8},[],{"trials":1318,"activeCount":8},[1319,1328,1337,1348],{"nctId":1320,"briefTitle":1321,"status":57,"phases":1322,"primaryCompletion":1323,"completion":1323,"start":297,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT01123876","Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor",[36],"2015-01",60,[1326],"Gastric Cancer",[1313],{"nctId":1329,"briefTitle":1330,"status":57,"phases":1331,"primaryCompletion":1323,"completion":1323,"start":147,"enrollment":285,"conditions":1332,"interventions":1334},"NCT01589419","A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer",[36],[1333],"Locally Advanced Rectal Cancer",[1335,1336],"veliparib","capecitabine",{"nctId":1338,"briefTitle":1339,"status":57,"phases":1340,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":1344,"interventions":1345},"NCT01063816","A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors",[36],"2016-08","2010-01",79,[1174],[1335,1346,1347],"carboplatin","gemcitabine",{"nctId":1349,"briefTitle":1350,"status":57,"phases":1351,"primaryCompletion":1352,"completion":1352,"start":1109,"enrollment":334,"conditions":1353,"interventions":1355},"NCT01617928","A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors",[36],"2013-07",[1354],"Solid Tumors",[1335,1346,1218],{"trials":1357,"activeCount":8},[1358,1368],{"nctId":1359,"briefTitle":1360,"status":57,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT01657799","Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer",[37],"2015-01-22","2012-10-19",307,[1366],"Brain Metastases From Non-small Cell Lung Cancer",[1313],{"nctId":1369,"briefTitle":1370,"status":57,"phases":1371,"primaryCompletion":397,"completion":397,"start":333,"enrollment":1372,"conditions":1373,"interventions":1375},"NCT01560104","A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer",[37],160,[1374],"Non-Small -Cell Lung Cancer",[1313,1228,1218],{"trials":1377,"activeCount":8},[],{"trials":1379,"activeCount":8},[],{"trials":1381,"activeCount":8},[],{"intervention":1383,"totalTrials":519,"cells":1384},"ABT-089",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1386,"activeCount":8},[],{"trials":1388,"activeCount":8},[],{"trials":1390,"activeCount":8},[1391,1399,1407,1414,1423],{"nctId":1392,"briefTitle":1393,"status":57,"phases":1394,"primaryCompletion":499,"completion":499,"start":1395,"enrollment":1372,"conditions":1396,"interventions":1398},"NCT00640185","Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[37],"2008-03",[1397],"Attention-Deficit\u002FHyperactivity Disorder",[1383],{"nctId":1400,"briefTitle":1401,"status":57,"phases":1402,"primaryCompletion":72,"completion":72,"start":1182,"enrollment":1403,"conditions":1404,"interventions":1405},"NCT00528697","A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[37],278,[1397],[1383,1406],"atomoxetine",{"nctId":1408,"briefTitle":1409,"status":57,"phases":1410,"primaryCompletion":1191,"completion":1191,"start":542,"enrollment":1411,"conditions":1412,"interventions":1413},"NCT00686933","Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[37],117,[1397],[1383],{"nctId":1415,"briefTitle":1416,"status":57,"phases":1417,"primaryCompletion":1191,"completion":1191,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},"NCT00443391","A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)",[37],"2007-02",141,[1421],"Attention Deficit Hyperactivity Disorder",[1383],{"nctId":1424,"briefTitle":1425,"status":57,"phases":1426,"primaryCompletion":555,"completion":555,"start":1395,"enrollment":1427,"conditions":1428,"interventions":1429},"NCT00640419","Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[37],121,[1397],[1383],{"trials":1431,"activeCount":8},[],{"trials":1433,"activeCount":8},[],{"trials":1435,"activeCount":8},[],{"intervention":1437,"totalTrials":519,"cells":1438},"ABT-263",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1469,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1440,"activeCount":8},[],{"trials":1442,"activeCount":8},[1443,1451,1460],{"nctId":1444,"briefTitle":1445,"status":57,"phases":1446,"primaryCompletion":1447,"completion":1447,"start":1142,"enrollment":334,"conditions":1448,"interventions":1449},"NCT00878449","A Study Evaluating the Safety of ABT-263 in Combination With Etoposide\u002FCisplatin in Subjects With Cancer",[36],"2011-07",[1354],[1437,1450],"etoposide\u002Fcisplatin",{"nctId":1452,"briefTitle":1453,"status":57,"phases":1454,"primaryCompletion":269,"completion":269,"start":71,"enrollment":285,"conditions":1455,"interventions":1457},"NCT00868413","Study of ABT-263 When Administered in Combination With Either Fludarabine\u002FCyclophosphamide\u002FRituximab or Bendamustine\u002FRituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia",[36],[1456],"Chronic Lymphocytic Leukemia",[1437,1458,1459],"FCR","BR",{"nctId":1461,"briefTitle":1462,"status":57,"phases":1463,"primaryCompletion":332,"completion":332,"start":1142,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT01009073","A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects",[36],51,[1354],[1437,1467,1468,1468],"erlotinib","irinotecan",{"trials":1470,"activeCount":8},[1471,1485],{"nctId":1472,"briefTitle":1473,"status":57,"phases":1474,"primaryCompletion":461,"completion":461,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1484},"NCT00406809","A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies",[36,37],"2006-11",81,[1478,1479,1480,1481,1482,1483],"Chronic Lymphoid Leukemia","Lymphoid Malignancies","Non-Hodgkin's Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Peripheral T-cell Lymphoma",[1437],{"nctId":1486,"briefTitle":1487,"status":57,"phases":1488,"primaryCompletion":61,"completion":61,"start":1489,"enrollment":210,"conditions":1490,"interventions":1493},"NCT00445198","A Phase 1\u002F2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies",[36,37],"2007-04",[1491,1492],"Small Cell Lung Cancer","Small Cell Lung Carcinoma",[1437],{"trials":1495,"activeCount":8},[],{"trials":1497,"activeCount":8},[],{"trials":1499,"activeCount":8},[],{"intervention":1501,"totalTrials":133,"cells":1502},"ABT-888",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1528,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1504,"activeCount":8},[],{"trials":1506,"activeCount":8},[1507,1516],{"nctId":1508,"briefTitle":1509,"status":57,"phases":1510,"primaryCompletion":295,"completion":295,"start":1511,"enrollment":500,"conditions":1512,"interventions":1514},"NCT01085422","A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer",[36],"2010-04",[1513],"Prostate Cancer",[1501,1515],"temozolomide",{"nctId":1517,"briefTitle":1518,"status":57,"phases":1519,"primaryCompletion":159,"completion":159,"start":1395,"enrollment":1520,"conditions":1521,"interventions":1527},"NCT00649207","A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases",[36],80,[1522,1523,1524,1525,1526],"Brain Diseases","Brain Neoplasms","Central Nervous System Diseases","Neoplasm Metastasis","Nervous System Neoplasms",[1501],{"trials":1529,"activeCount":8},[1530,1541],{"nctId":1531,"briefTitle":1532,"status":57,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1171,"enrollment":1535,"conditions":1536,"interventions":1540},"NCT00804908","A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma",[37],"2016-01",346,[1537,1538,1539],"Melanoma","Metastatic Melanoma","Skin Cancer",[1515,1501],{"nctId":1542,"briefTitle":1543,"status":57,"phases":1544,"primaryCompletion":332,"completion":332,"start":297,"enrollment":1545,"conditions":1546,"interventions":1548},"NCT01113957","A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer",[37],168,[1547],"Ovarian Cancer",[1501,1549,1515],"pegylated liposomal doxorubicin",{"trials":1551,"activeCount":8},[],{"trials":1553,"activeCount":8},[],{"trials":1555,"activeCount":8},[],{"intervention":1218,"totalTrials":133,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1566,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1559,"activeCount":8},[],{"trials":1561,"activeCount":8},[1562],{"nctId":1349,"briefTitle":1350,"status":57,"phases":1563,"primaryCompletion":1352,"completion":1352,"start":1109,"enrollment":334,"conditions":1564,"interventions":1565},[36],[1354],[1335,1346,1218],{"trials":1567,"activeCount":8},[1568,1572,1576],{"nctId":1212,"briefTitle":1213,"status":57,"phases":1569,"primaryCompletion":773,"completion":773,"start":555,"enrollment":21,"conditions":1570,"interventions":1571},[37],[1216],[1160,1218],{"nctId":1220,"briefTitle":1221,"status":57,"phases":1573,"primaryCompletion":82,"completion":82,"start":1223,"enrollment":1224,"conditions":1574,"interventions":1575},[37],[1226],[1160,1160,1228,1229],{"nctId":1369,"briefTitle":1370,"status":57,"phases":1577,"primaryCompletion":397,"completion":397,"start":333,"enrollment":1372,"conditions":1578,"interventions":1579},[37],[1374],[1313,1228,1218],{"trials":1581,"activeCount":8},[],{"trials":1583,"activeCount":8},[],{"trials":1585,"activeCount":8},[],{"intervention":1128,"totalTrials":133,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1589,"activeCount":8},[],{"trials":1591,"activeCount":8},[],{"trials":1593,"activeCount":8},[1594,1598,1606,1610],{"nctId":1122,"briefTitle":1123,"status":57,"phases":1595,"primaryCompletion":389,"completion":389,"start":333,"enrollment":1125,"conditions":1596,"interventions":1597},[37],[1094],[1128,1078],{"nctId":1599,"briefTitle":1600,"status":57,"phases":1601,"primaryCompletion":342,"completion":342,"start":773,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT01018875","Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",[37],242,[1094],[1605,1128],"ABT-288",{"nctId":1138,"briefTitle":1139,"status":57,"phases":1607,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":1143,"conditions":1608,"interventions":1609},[37],[1094],[1078,1128],{"nctId":1611,"briefTitle":1612,"status":57,"phases":1613,"primaryCompletion":1447,"completion":1447,"start":498,"enrollment":1614,"conditions":1615,"interventions":1616},"NCT01137526","Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease",[37],267,[1094],[1617,1128],"ABT-384",{"trials":1619,"activeCount":8},[],{"trials":1621,"activeCount":8},[],{"trials":1623,"activeCount":8},[],{"intervention":1228,"totalTrials":133,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1638,"PHASE3":1648,"PHASE4":1650,"NA":1652},{"trials":1627,"activeCount":8},[],{"trials":1629,"activeCount":8},[1630,1634],{"nctId":1338,"briefTitle":1339,"status":57,"phases":1631,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":1632,"interventions":1633},[36],[1174],[1335,1346,1347],{"nctId":1349,"briefTitle":1350,"status":57,"phases":1635,"primaryCompletion":1352,"completion":1352,"start":1109,"enrollment":334,"conditions":1636,"interventions":1637},[36],[1354],[1335,1346,1218],{"trials":1639,"activeCount":8},[1640,1644],{"nctId":1220,"briefTitle":1221,"status":57,"phases":1641,"primaryCompletion":82,"completion":82,"start":1223,"enrollment":1224,"conditions":1642,"interventions":1643},[37],[1226],[1160,1160,1228,1229],{"nctId":1369,"briefTitle":1370,"status":57,"phases":1645,"primaryCompletion":397,"completion":397,"start":333,"enrollment":1372,"conditions":1646,"interventions":1647},[37],[1374],[1313,1228,1218],{"trials":1649,"activeCount":8},[],{"trials":1651,"activeCount":8},[],{"trials":1653,"activeCount":8},[],{"intervention":304,"totalTrials":607,"cells":1655},{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1657,"activeCount":8},[],{"trials":1659,"activeCount":8},[],{"trials":1661,"activeCount":8},[1662,1666,1673],{"nctId":292,"briefTitle":293,"status":57,"phases":1663,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":1664,"interventions":1665},[37],[300,301,23,302],[275,304,305,306,307,256],{"nctId":1667,"briefTitle":1668,"status":57,"phases":1669,"primaryCompletion":1511,"completion":1511,"start":554,"enrollment":519,"conditions":1670,"interventions":1672},"NCT00872196","A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies",[37],[1671],"Hepatitis C Virus Infection",[304],{"nctId":367,"briefTitle":368,"status":57,"phases":1674,"primaryCompletion":370,"completion":82,"start":95,"enrollment":18,"conditions":1675,"interventions":1676},[37],[300,301,23,302],[275,304,256,306],{"trials":1678,"activeCount":8},[],{"trials":1680,"activeCount":8},[],{"trials":1682,"activeCount":8},[],{"intervention":1515,"totalTrials":607,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1693,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1686,"activeCount":8},[],{"trials":1688,"activeCount":8},[1689],{"nctId":1508,"briefTitle":1509,"status":57,"phases":1690,"primaryCompletion":295,"completion":295,"start":1511,"enrollment":500,"conditions":1691,"interventions":1692},[36],[1513],[1501,1515],{"trials":1694,"activeCount":8},[1695,1699],{"nctId":1531,"briefTitle":1532,"status":57,"phases":1696,"primaryCompletion":1534,"completion":1534,"start":1171,"enrollment":1535,"conditions":1697,"interventions":1698},[37],[1537,1538,1539],[1515,1501],{"nctId":1542,"briefTitle":1543,"status":57,"phases":1700,"primaryCompletion":332,"completion":332,"start":297,"enrollment":1545,"conditions":1701,"interventions":1702},[37],[1547],[1501,1549,1515],{"trials":1704,"activeCount":8},[],{"trials":1706,"activeCount":8},[],{"trials":1708,"activeCount":8},[],{"intervention":1710,"totalTrials":607,"cells":1711},"Hydrocodone\u002FAcetaminophen Extended Release",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1713,"activeCount":8},[],{"trials":1715,"activeCount":8},[],{"trials":1717,"activeCount":8},[1718,1728,1735],{"nctId":1719,"briefTitle":1720,"status":57,"phases":1721,"primaryCompletion":498,"completion":498,"start":773,"enrollment":1722,"conditions":1723,"interventions":1725},"NCT01038609","Hydrocodone\u002FAcetaminophen for Acute Pain Following Bunionectomy",[37],250,[1724],"Pain",[1710,1726,1727],"Acetaminophen","Morphine Extended Release",{"nctId":1729,"briefTitle":1730,"status":57,"phases":1731,"primaryCompletion":295,"completion":295,"start":184,"enrollment":1732,"conditions":1733,"interventions":1734},"NCT01333722","Acute Pain Study Following Bunionectomy",[37],100,[1724],[1710],{"nctId":1736,"briefTitle":1737,"status":57,"phases":1738,"primaryCompletion":351,"completion":351,"start":295,"enrollment":1545,"conditions":1739,"interventions":1740},"NCT01364922","Phase 2 Chronic Low Back Pain Study",[37],[739],[1741],"hydrocodone\u002Facetaminophen extended release",{"trials":1743,"activeCount":8},[],{"trials":1745,"activeCount":8},[],{"trials":1747,"activeCount":8},[],{"intervention":289,"totalTrials":193,"cells":1749},{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1751,"activeCount":8},[],{"trials":1753,"activeCount":8},[],{"trials":1755,"activeCount":8},[1756,1760],{"nctId":280,"briefTitle":281,"status":57,"phases":1757,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":1758,"interventions":1759},[37],[287],[289,276,290,256],{"nctId":309,"briefTitle":310,"status":57,"phases":1761,"primaryCompletion":312,"completion":60,"start":313,"enrollment":314,"conditions":1762,"interventions":1763},[37],[316],[289,276,256],{"trials":1765,"activeCount":8},[],{"trials":1767,"activeCount":8},[],{"trials":1769,"activeCount":8},[],{"intervention":1771,"totalTrials":193,"cells":1772},"ABT-639",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1774,"activeCount":8},[],{"trials":1776,"activeCount":8},[],{"trials":1778,"activeCount":8},[1779,1788],{"nctId":1780,"briefTitle":1781,"status":57,"phases":1782,"primaryCompletion":351,"completion":351,"start":184,"enrollment":1783,"conditions":1784,"interventions":1786},"NCT01345045","A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain",[37],193,[1785],"Diabetic Neuropathic Pain",[1771,1787],"pregabalin",{"nctId":1789,"briefTitle":1790,"status":57,"phases":1791,"primaryCompletion":390,"completion":390,"start":82,"enrollment":160,"conditions":1792,"interventions":1793},"NCT01589432","A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy",[37],[1785],[1771,1794],"Lidocaine",{"trials":1796,"activeCount":8},[],{"trials":1798,"activeCount":8},[],{"trials":1800,"activeCount":8},[],{"intervention":327,"totalTrials":193,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1817,"PHASE4":1819,"NA":1821},{"trials":1804,"activeCount":8},[],{"trials":1806,"activeCount":8},[],{"trials":1808,"activeCount":8},[1809,1813],{"nctId":319,"briefTitle":320,"status":57,"phases":1810,"primaryCompletion":296,"completion":322,"start":183,"enrollment":323,"conditions":1811,"interventions":1812},[37],[287,325],[276,327,256],{"nctId":357,"briefTitle":358,"status":57,"phases":1814,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":1815,"interventions":1816},[37],[364],[305,327,256],{"trials":1818,"activeCount":8},[],{"trials":1820,"activeCount":8},[],{"trials":1822,"activeCount":8},[],{"intervention":1824,"totalTrials":193,"cells":1825},"Duloxetine",{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1830,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1827,"activeCount":8},[],{"trials":1829,"activeCount":8},[],{"trials":1831,"activeCount":8},[1832,1841],{"nctId":1833,"briefTitle":1834,"status":1089,"phases":1835,"primaryCompletion":1109,"completion":1109,"start":82,"enrollment":229,"conditions":1836,"interventions":1837},"NCT01579279","A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain",[37],[1785],[1838,1839,1840,1824],"ABT-652 6 mg","ABT-652 12 mg","ABT-652 12 mg - 18 mg",{"nctId":1842,"briefTitle":1843,"status":57,"phases":1844,"primaryCompletion":1191,"completion":1191,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1853},"NCT00507936","Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain",[37],"2007-08",280,[1848,1849,1850,1851,1852],"Diabetic Neuralgia","Diabetic Neuropathies","Diabetic Neuropathy, Painful","Diabetic Polyneuropathy","Neuralgia, Diabetic",[1854,1854,1854,1824],"ABT-894",{"trials":1856,"activeCount":8},[],{"trials":1858,"activeCount":8},[],{"trials":1860,"activeCount":8},[],{"intervention":1854,"totalTrials":193,"cells":1862},{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1864,"activeCount":8},[],{"trials":1866,"activeCount":8},[],{"trials":1868,"activeCount":8},[1869,1873],{"nctId":1842,"briefTitle":1843,"status":57,"phases":1870,"primaryCompletion":1191,"completion":1191,"start":1845,"enrollment":1846,"conditions":1871,"interventions":1872},[37],[1848,1849,1850,1851,1852],[1854,1854,1854,1824],{"nctId":1874,"briefTitle":1875,"status":57,"phases":1876,"primaryCompletion":900,"completion":900,"start":563,"enrollment":1877,"conditions":1878,"interventions":1879},"NCT00548925","A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain",[37],124,[1785],[1854],{"trials":1881,"activeCount":8},[],{"trials":1883,"activeCount":8},[],{"trials":1885,"activeCount":8},[],{"intervention":1347,"totalTrials":193,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1896,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1889,"activeCount":8},[],{"trials":1891,"activeCount":8},[1892],{"nctId":1338,"briefTitle":1339,"status":57,"phases":1893,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":1894,"interventions":1895},[36],[1174],[1335,1346,1347],{"trials":1897,"activeCount":8},[1898],{"nctId":1899,"briefTitle":1900,"status":57,"phases":1901,"primaryCompletion":1223,"completion":1223,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1906},"NCT00401570","A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer",[37],"2005-03",40,[1905],"Pancreatic Cancer",[1907,1908],"Volociximab","Gemcitabine",{"trials":1910,"activeCount":8},[],{"trials":1912,"activeCount":8},[],{"trials":1914,"activeCount":8},[],{"intervention":1916,"totalTrials":193,"cells":1917},"Atrasentan",{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1919,"activeCount":8},[],{"trials":1921,"activeCount":8},[],{"trials":1923,"activeCount":8},[1924,1932],{"nctId":1925,"briefTitle":1926,"status":57,"phases":1927,"primaryCompletion":313,"completion":313,"start":184,"enrollment":1928,"conditions":1929,"interventions":1931},"NCT01356849","Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor",[37],149,[32,1930],"Diabetic Nephropathy",[1916],{"nctId":1933,"briefTitle":1934,"status":57,"phases":1935,"primaryCompletion":94,"completion":94,"start":796,"enrollment":1936,"conditions":1937,"interventions":1938},"NCT01399580","A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy",[37],48,[32,1930],[1916],{"trials":1940,"activeCount":8},[],{"trials":1942,"activeCount":8},[],{"trials":1944,"activeCount":8},[],{"intervention":1946,"totalTrials":229,"cells":1947},"Adalimumab, current formulation",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1949,"activeCount":8},[],{"trials":1951,"activeCount":8},[],{"trials":1953,"activeCount":8},[1954],{"nctId":1955,"briefTitle":1956,"status":57,"phases":1957,"primaryCompletion":269,"completion":269,"start":147,"enrollment":1732,"conditions":1958,"interventions":1959},"NCT01712178","A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety",[37],[14],[1946,1960],"Adalimumab, new formulation",{"trials":1962,"activeCount":8},[],{"trials":1964,"activeCount":8},[],{"trials":1966,"activeCount":8},[],{"intervention":1960,"totalTrials":229,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1979,"PHASE4":1981,"NA":1983},{"trials":1970,"activeCount":8},[],{"trials":1972,"activeCount":8},[],{"trials":1974,"activeCount":8},[1975],{"nctId":1955,"briefTitle":1956,"status":57,"phases":1976,"primaryCompletion":269,"completion":269,"start":147,"enrollment":1732,"conditions":1977,"interventions":1978},[37],[14],[1946,1960],{"trials":1980,"activeCount":8},[],{"trials":1982,"activeCount":8},[],{"trials":1984,"activeCount":8},[],{"intervention":1986,"totalTrials":229,"cells":1987},"ABT-712 Extended-release",{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1989,"activeCount":8},[],{"trials":1991,"activeCount":8},[],{"trials":1993,"activeCount":8},[1994],{"nctId":1995,"briefTitle":1996,"status":57,"phases":1997,"primaryCompletion":1998,"completion":1998,"start":170,"enrollment":1999,"conditions":2000,"interventions":2001},"NCT00935311","Hydrocodone\u002FAcetaminophen for Acute Pain Following Third Molar Tooth Extraction",[37],"2009-08",122,[1724],[1986,2002],"Hydrocodone\u002FAcetaminophen Immediate-release",{"trials":2004,"activeCount":8},[],{"trials":2006,"activeCount":8},[],{"trials":2008,"activeCount":8},[],{"intervention":2002,"totalTrials":229,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":8},[],{"trials":2014,"activeCount":8},[],{"trials":2016,"activeCount":8},[2017],{"nctId":1995,"briefTitle":1996,"status":57,"phases":2018,"primaryCompletion":1998,"completion":1998,"start":170,"enrollment":1999,"conditions":2019,"interventions":2020},[37],[1724],[1986,2002],{"trials":2022,"activeCount":8},[],{"trials":2024,"activeCount":8},[],{"trials":2026,"activeCount":8},[],{"intervention":2028,"totalTrials":229,"cells":2029},"ABT-SLV187",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2031,"activeCount":8},[],{"trials":2033,"activeCount":8},[],{"trials":2035,"activeCount":8},[2036],{"nctId":2037,"briefTitle":2038,"status":57,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":351,"enrollment":26,"conditions":2041,"interventions":2042},"NCT01479127","Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease",[37],"2012-07",[151],[2028,2043],"Oral Levodopa\u002FCarbidopa",{"trials":2045,"activeCount":8},[],{"trials":2047,"activeCount":8},[],{"trials":2049,"activeCount":8},[],{"intervention":2043,"totalTrials":229,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":8},[],{"trials":2055,"activeCount":8},[],{"trials":2057,"activeCount":8},[2058],{"nctId":2037,"briefTitle":2038,"status":57,"phases":2059,"primaryCompletion":2040,"completion":2040,"start":351,"enrollment":26,"conditions":2060,"interventions":2061},[37],[151],[2028,2043],{"trials":2063,"activeCount":8},[],{"trials":2065,"activeCount":8},[],{"trials":2067,"activeCount":8},[],{"intervention":2069,"totalTrials":229,"cells":2070},"ABT-436",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2072,"activeCount":8},[],{"trials":2074,"activeCount":8},[],{"trials":2076,"activeCount":8},[2077],{"nctId":2078,"briefTitle":2079,"status":1089,"phases":2080,"primaryCompletion":415,"completion":2081,"start":296,"enrollment":2082,"conditions":2083,"interventions":2085},"NCT01741142","Efficacy and Safety Study of ABT-436 in Major Depressive Disorder",[37],"2015-08",19,[2084],"Major Depressive Disorder",[2069,2086],"Escitalopram",{"trials":2088,"activeCount":8},[],{"trials":2090,"activeCount":8},[],{"trials":2092,"activeCount":8},[],{"intervention":2086,"totalTrials":229,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":8},[],{"trials":2098,"activeCount":8},[],{"trials":2100,"activeCount":8},[2101],{"nctId":2078,"briefTitle":2079,"status":1089,"phases":2102,"primaryCompletion":415,"completion":2081,"start":296,"enrollment":2082,"conditions":2103,"interventions":2104},[37],[2084],[2069,2086],{"trials":2106,"activeCount":8},[],{"trials":2108,"activeCount":8},[],{"trials":2110,"activeCount":8},[],{"intervention":290,"totalTrials":229,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2114,"activeCount":8},[],{"trials":2116,"activeCount":8},[],{"trials":2118,"activeCount":8},[2119],{"nctId":280,"briefTitle":281,"status":57,"phases":2120,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":2121,"interventions":2122},[37],[287],[289,276,290,256],{"trials":2124,"activeCount":8},[],{"trials":2126,"activeCount":8},[],{"trials":2128,"activeCount":8},[],{"intervention":2130,"totalTrials":229,"cells":2131},"M200",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2148,"PHASE4":2150,"NA":2152},{"trials":2133,"activeCount":8},[],{"trials":2135,"activeCount":8},[],{"trials":2137,"activeCount":8},[2138],{"nctId":2139,"briefTitle":2140,"status":57,"phases":2141,"primaryCompletion":1191,"completion":1142,"start":2142,"enrollment":2143,"conditions":2144,"interventions":2146},"NCT00635193","Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)",[36,37],"2007-07",138,[2145],"Ovarian Cancer, Primary Peritoneal Cancer",[2130,2147,2130,2130],"Liposomal Doxorubicin",{"trials":2149,"activeCount":8},[],{"trials":2151,"activeCount":8},[],{"trials":2153,"activeCount":8},[],{"intervention":2147,"totalTrials":229,"cells":2155},{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2166,"PHASE4":2168,"NA":2170},{"trials":2157,"activeCount":8},[],{"trials":2159,"activeCount":8},[],{"trials":2161,"activeCount":8},[2162],{"nctId":2139,"briefTitle":2140,"status":57,"phases":2163,"primaryCompletion":1191,"completion":1142,"start":2142,"enrollment":2143,"conditions":2164,"interventions":2165},[36,37],[2145],[2130,2147,2130,2130],{"trials":2167,"activeCount":8},[],{"trials":2169,"activeCount":8},[],{"trials":2171,"activeCount":8},[],{"intervention":1198,"totalTrials":229,"cells":2173},{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2175,"activeCount":8},[],{"trials":2177,"activeCount":8},[],{"trials":2179,"activeCount":8},[2180],{"nctId":1188,"briefTitle":1189,"status":57,"phases":2181,"primaryCompletion":1109,"completion":1109,"start":1191,"enrollment":1192,"conditions":2182,"interventions":2183},[37],[1194,1195,1196],[1160,1198,1199,1200,1201,1160],{"trials":2185,"activeCount":8},[],{"trials":2187,"activeCount":8},[],{"trials":2189,"activeCount":8},[],{"intervention":1199,"totalTrials":229,"cells":2191},{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2202,"PHASE4":2204,"NA":2206},{"trials":2193,"activeCount":8},[],{"trials":2195,"activeCount":8},[],{"trials":2197,"activeCount":8},[2198],{"nctId":1188,"briefTitle":1189,"status":57,"phases":2199,"primaryCompletion":1109,"completion":1109,"start":1191,"enrollment":1192,"conditions":2200,"interventions":2201},[37],[1194,1195,1196],[1160,1198,1199,1200,1201,1160],{"trials":2203,"activeCount":8},[],{"trials":2205,"activeCount":8},[],{"trials":2207,"activeCount":8},[],{"intervention":1200,"totalTrials":229,"cells":2209},{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2220,"PHASE4":2222,"NA":2224},{"trials":2211,"activeCount":8},[],{"trials":2213,"activeCount":8},[],{"trials":2215,"activeCount":8},[2216],{"nctId":1188,"briefTitle":1189,"status":57,"phases":2217,"primaryCompletion":1109,"completion":1109,"start":1191,"enrollment":1192,"conditions":2218,"interventions":2219},[37],[1194,1195,1196],[1160,1198,1199,1200,1201,1160],{"trials":2221,"activeCount":8},[],{"trials":2223,"activeCount":8},[],{"trials":2225,"activeCount":8},[],{"intervention":1201,"totalTrials":229,"cells":2227},{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2238,"PHASE4":2240,"NA":2242},{"trials":2229,"activeCount":8},[],{"trials":2231,"activeCount":8},[],{"trials":2233,"activeCount":8},[2234],{"nctId":1188,"briefTitle":1189,"status":57,"phases":2235,"primaryCompletion":1109,"completion":1109,"start":1191,"enrollment":1192,"conditions":2236,"interventions":2237},[37],[1194,1195,1196],[1160,1198,1199,1200,1201,1160],{"trials":2239,"activeCount":8},[],{"trials":2241,"activeCount":8},[],{"trials":2243,"activeCount":8},[],{"intervention":1787,"totalTrials":229,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2247,"activeCount":8},[],{"trials":2249,"activeCount":8},[],{"trials":2251,"activeCount":8},[2252],{"nctId":1780,"briefTitle":1781,"status":57,"phases":2253,"primaryCompletion":351,"completion":351,"start":184,"enrollment":1783,"conditions":2254,"interventions":2255},[37],[1785],[1771,1787],{"trials":2257,"activeCount":8},[],{"trials":2259,"activeCount":8},[],{"trials":2261,"activeCount":8},[],{"intervention":307,"totalTrials":229,"cells":2263},{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2274,"PHASE4":2276,"NA":2278},{"trials":2265,"activeCount":8},[],{"trials":2267,"activeCount":8},[],{"trials":2269,"activeCount":8},[2270],{"nctId":292,"briefTitle":293,"status":57,"phases":2271,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":2272,"interventions":2273},[37],[300,301,23,302],[275,304,305,306,307,256],{"trials":2275,"activeCount":8},[],{"trials":2277,"activeCount":8},[],{"trials":2279,"activeCount":8},[],{"intervention":1406,"totalTrials":229,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2292,"PHASE4":2294,"NA":2296},{"trials":2283,"activeCount":8},[],{"trials":2285,"activeCount":8},[],{"trials":2287,"activeCount":8},[2288],{"nctId":1400,"briefTitle":1401,"status":57,"phases":2289,"primaryCompletion":72,"completion":72,"start":1182,"enrollment":1403,"conditions":2290,"interventions":2291},[37],[1397],[1383,1406],{"trials":2293,"activeCount":8},[],{"trials":2295,"activeCount":8},[],{"trials":2297,"activeCount":8},[],{"intervention":2299,"totalTrials":229,"cells":2300},"ABT-751",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2302,"activeCount":8},[],{"trials":2304,"activeCount":8},[],{"trials":2306,"activeCount":8},[2307],{"nctId":2308,"briefTitle":2309,"status":57,"phases":2310,"primaryCompletion":107,"completion":107,"start":1475,"enrollment":2311,"conditions":2312,"interventions":2316},"NCT00297089","A Phase 1\u002F2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer",[36,37],165,[2313,2314,2315],"Lung Cancer","NSCLC","Non-Small-Cell Lung Cancer",[2299,2317],"pemetrexed",{"trials":2319,"activeCount":8},[],{"trials":2321,"activeCount":8},[],{"trials":2323,"activeCount":8},[],{"intervention":2317,"totalTrials":229,"cells":2325},{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2336,"PHASE4":2338,"NA":2340},{"trials":2327,"activeCount":8},[],{"trials":2329,"activeCount":8},[],{"trials":2331,"activeCount":8},[2332],{"nctId":2308,"briefTitle":2309,"status":57,"phases":2333,"primaryCompletion":107,"completion":107,"start":1475,"enrollment":2311,"conditions":2334,"interventions":2335},[36,37],[2313,2314,2315],[2299,2317],{"trials":2337,"activeCount":8},[],{"trials":2339,"activeCount":8},[],{"trials":2341,"activeCount":8},[],{"intervention":1838,"totalTrials":229,"cells":2343},{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2345,"activeCount":8},[],{"trials":2347,"activeCount":8},[],{"trials":2349,"activeCount":8},[2350],{"nctId":1833,"briefTitle":1834,"status":1089,"phases":2351,"primaryCompletion":1109,"completion":1109,"start":82,"enrollment":229,"conditions":2352,"interventions":2353},[37],[1785],[1838,1839,1840,1824],{"trials":2355,"activeCount":8},[],{"trials":2357,"activeCount":8},[],{"trials":2359,"activeCount":8},[],{"intervention":1839,"totalTrials":229,"cells":2361},{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[],{"trials":2367,"activeCount":8},[2368],{"nctId":1833,"briefTitle":1834,"status":1089,"phases":2369,"primaryCompletion":1109,"completion":1109,"start":82,"enrollment":229,"conditions":2370,"interventions":2371},[37],[1785],[1838,1839,1840,1824],{"trials":2373,"activeCount":8},[],{"trials":2375,"activeCount":8},[],{"trials":2377,"activeCount":8},[],{"intervention":1840,"totalTrials":229,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":8},[],{"trials":2383,"activeCount":8},[],{"trials":2385,"activeCount":8},[2386],{"nctId":1833,"briefTitle":1834,"status":1089,"phases":2387,"primaryCompletion":1109,"completion":1109,"start":82,"enrollment":229,"conditions":2388,"interventions":2389},[37],[1785],[1838,1839,1840,1824],{"trials":2391,"activeCount":8},[],{"trials":2393,"activeCount":8},[],{"trials":2395,"activeCount":8},[],{"intervention":1726,"totalTrials":229,"cells":2397},{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2408,"PHASE4":2410,"NA":2412},{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[],{"trials":2403,"activeCount":8},[2404],{"nctId":1719,"briefTitle":1720,"status":57,"phases":2405,"primaryCompletion":498,"completion":498,"start":773,"enrollment":1722,"conditions":2406,"interventions":2407},[37],[1724],[1710,1726,1727],{"trials":2409,"activeCount":8},[],{"trials":2411,"activeCount":8},[],{"trials":2413,"activeCount":8},[],{"intervention":1727,"totalTrials":229,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2417,"activeCount":8},[],{"trials":2419,"activeCount":8},[],{"trials":2421,"activeCount":8},[2422],{"nctId":1719,"briefTitle":1720,"status":57,"phases":2423,"primaryCompletion":498,"completion":498,"start":773,"enrollment":1722,"conditions":2424,"interventions":2425},[37],[1724],[1710,1726,1727],{"trials":2427,"activeCount":8},[],{"trials":2429,"activeCount":8},[],{"trials":2431,"activeCount":8},[],{"intervention":2433,"totalTrials":229,"cells":2434},"elotuzumab",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2436,"activeCount":8},[],{"trials":2438,"activeCount":8},[],{"trials":2440,"activeCount":8},[2441],{"nctId":2442,"briefTitle":2443,"status":57,"phases":2444,"primaryCompletion":461,"completion":461,"start":499,"enrollment":2445,"conditions":2446,"interventions":2448},"NCT00742560","A Phase 1b\u002F2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma",[37],101,[2447],"Hematologic Cancer",[2433,2449,2450,2450],"lenalidomide","dexamethasone",{"trials":2452,"activeCount":8},[],{"trials":2454,"activeCount":8},[],{"trials":2456,"activeCount":8},[],{"intervention":2449,"totalTrials":229,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2460,"activeCount":8},[],{"trials":2462,"activeCount":8},[],{"trials":2464,"activeCount":8},[2465],{"nctId":2442,"briefTitle":2443,"status":57,"phases":2466,"primaryCompletion":461,"completion":461,"start":499,"enrollment":2445,"conditions":2467,"interventions":2468},[37],[2447],[2433,2449,2450,2450],{"trials":2470,"activeCount":8},[],{"trials":2472,"activeCount":8},[],{"trials":2474,"activeCount":8},[],{"intervention":2450,"totalTrials":229,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":8},[],{"trials":2480,"activeCount":8},[],{"trials":2482,"activeCount":8},[2483],{"nctId":2442,"briefTitle":2443,"status":57,"phases":2484,"primaryCompletion":461,"completion":461,"start":499,"enrollment":2445,"conditions":2485,"interventions":2486},[37],[2447],[2433,2449,2450,2450],{"trials":2488,"activeCount":8},[],{"trials":2490,"activeCount":8},[],{"trials":2492,"activeCount":8},[],{"intervention":2494,"totalTrials":229,"cells":2495},"ABT-869 .25 mg\u002Fkg",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2511,"PHASE4":2513,"NA":2515},{"trials":2497,"activeCount":8},[],{"trials":2499,"activeCount":8},[],{"trials":2501,"activeCount":8},[2502],{"nctId":2503,"briefTitle":2504,"status":57,"phases":2505,"primaryCompletion":295,"completion":147,"start":1845,"enrollment":2506,"conditions":2507,"interventions":2509},"NCT00517790","Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)",[37],140,[2508],"Non-Small Cell Lung Cancer (NSCLC)",[2494,2510],"ABT-869 0.10 mg\u002Fkg",{"trials":2512,"activeCount":8},[],{"trials":2514,"activeCount":8},[],{"trials":2516,"activeCount":8},[],{"intervention":2510,"totalTrials":229,"cells":2518},{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2529,"PHASE4":2531,"NA":2533},{"trials":2520,"activeCount":8},[],{"trials":2522,"activeCount":8},[],{"trials":2524,"activeCount":8},[2525],{"nctId":2503,"briefTitle":2504,"status":57,"phases":2526,"primaryCompletion":295,"completion":147,"start":1845,"enrollment":2506,"conditions":2527,"interventions":2528},[37],[2508],[2494,2510],{"trials":2530,"activeCount":8},[],{"trials":2532,"activeCount":8},[],{"trials":2534,"activeCount":8},[],{"intervention":2536,"totalTrials":229,"cells":2537},"ABT-652 NSAID",{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2539,"activeCount":8},[],{"trials":2541,"activeCount":8},[],{"trials":2543,"activeCount":8},[2544],{"nctId":2545,"briefTitle":2546,"status":57,"phases":2547,"primaryCompletion":82,"completion":82,"start":351,"enrollment":2548,"conditions":2549,"interventions":2551},"NCT01444365","A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee",[37],202,[2550],"Osteoarthritis of the Knee",[2536],{"trials":2553,"activeCount":8},[],{"trials":2555,"activeCount":8},[],{"trials":2557,"activeCount":8},[],{"intervention":2559,"totalTrials":229,"cells":2560},"Anti IL-12 monoclonal antibody\u002FABT-874",{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2562,"activeCount":8},[],{"trials":2564,"activeCount":8},[],{"trials":2566,"activeCount":8},[2567],{"nctId":2568,"briefTitle":2569,"status":57,"phases":2570,"primaryCompletion":72,"completion":72,"start":2571,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT00292396","Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[37],"2005-11",180,[20],[2559],{"trials":2576,"activeCount":8},[],{"trials":2578,"activeCount":8},[],{"trials":2580,"activeCount":8},[],{"intervention":1549,"totalTrials":229,"cells":2582},{"EARLY_PHASE1":2583,"PHASE1":2585,"PHASE2":2587,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2584,"activeCount":8},[],{"trials":2586,"activeCount":8},[],{"trials":2588,"activeCount":8},[2589],{"nctId":1542,"briefTitle":1543,"status":57,"phases":2590,"primaryCompletion":332,"completion":332,"start":297,"enrollment":1545,"conditions":2591,"interventions":2592},[37],[1547],[1501,1549,1515],{"trials":2594,"activeCount":8},[],{"trials":2596,"activeCount":8},[],{"trials":2598,"activeCount":8},[],{"intervention":2600,"totalTrials":229,"cells":2601},"ABT-288 Low Dose",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2603,"activeCount":8},[],{"trials":2605,"activeCount":8},[],{"trials":2607,"activeCount":8},[2608],{"nctId":2609,"briefTitle":2610,"status":57,"phases":2611,"primaryCompletion":1447,"completion":1447,"start":297,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT01077700","Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia",[37],214,[1119],[2600,2615],"ABT-288 High Dose",{"trials":2617,"activeCount":8},[],{"trials":2619,"activeCount":8},[],{"trials":2621,"activeCount":8},[],{"intervention":2615,"totalTrials":229,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2634,"PHASE4":2636,"NA":2638},{"trials":2625,"activeCount":8},[],{"trials":2627,"activeCount":8},[],{"trials":2629,"activeCount":8},[2630],{"nctId":2609,"briefTitle":2610,"status":57,"phases":2631,"primaryCompletion":1447,"completion":1447,"start":297,"enrollment":2612,"conditions":2632,"interventions":2633},[37],[1119],[2600,2615],{"trials":2635,"activeCount":8},[],{"trials":2637,"activeCount":8},[],{"trials":2639,"activeCount":8},[],{"intervention":2641,"totalTrials":229,"cells":2642},"ABT-652",{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2647,"PHASE3":2657,"PHASE4":2659,"NA":2661},{"trials":2644,"activeCount":8},[],{"trials":2646,"activeCount":8},[],{"trials":2648,"activeCount":8},[2649],{"nctId":2650,"briefTitle":2651,"status":57,"phases":2652,"primaryCompletion":370,"completion":370,"start":117,"enrollment":2653,"conditions":2654,"interventions":2655},"NCT01207115","A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee",[37],322,[2550],[2641,2656],"Naproxen",{"trials":2658,"activeCount":8},[],{"trials":2660,"activeCount":8},[],{"trials":2662,"activeCount":8},[],{"intervention":2656,"totalTrials":229,"cells":2664},{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2669,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2666,"activeCount":8},[],{"trials":2668,"activeCount":8},[],{"trials":2670,"activeCount":8},[2671],{"nctId":2650,"briefTitle":2651,"status":57,"phases":2672,"primaryCompletion":370,"completion":370,"start":117,"enrollment":2653,"conditions":2673,"interventions":2674},[37],[2550],[2641,2656],{"trials":2676,"activeCount":8},[],{"trials":2678,"activeCount":8},[],{"trials":2680,"activeCount":8},[],{"intervention":2682,"totalTrials":229,"cells":2683},"ABT-874\u002FHuman monoclonal antibody against IL-12",{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2685,"activeCount":8},[],{"trials":2687,"activeCount":8},[],{"trials":2689,"activeCount":8},[2690],{"nctId":2691,"briefTitle":2692,"status":57,"phases":2693,"primaryCompletion":1475,"completion":1475,"start":81,"enrollment":2694,"conditions":2695,"interventions":2697},"NCT00086671","Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)",[37],215,[2696],"Multiple Sclerosis",[2682],{"trials":2699,"activeCount":8},[],{"trials":2701,"activeCount":8},[],{"trials":2703,"activeCount":8},[],{"intervention":1605,"totalTrials":229,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2707,"activeCount":8},[],{"trials":2709,"activeCount":8},[],{"trials":2711,"activeCount":8},[2712],{"nctId":1599,"briefTitle":1600,"status":57,"phases":2713,"primaryCompletion":342,"completion":342,"start":773,"enrollment":1602,"conditions":2714,"interventions":2715},[37],[1094],[1605,1128],{"trials":2717,"activeCount":8},[],{"trials":2719,"activeCount":8},[],{"trials":2721,"activeCount":8},[],{"intervention":1617,"totalTrials":229,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2725,"activeCount":8},[],{"trials":2727,"activeCount":8},[],{"trials":2729,"activeCount":8},[2730],{"nctId":1611,"briefTitle":1612,"status":57,"phases":2731,"primaryCompletion":1447,"completion":1447,"start":498,"enrollment":1614,"conditions":2732,"interventions":2733},[37],[1094],[1617,1128],{"trials":2735,"activeCount":8},[],{"trials":2737,"activeCount":8},[],{"trials":2739,"activeCount":8},[],{"intervention":2741,"totalTrials":229,"cells":2742},"Navitoclax",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2744,"activeCount":8},[],{"trials":2746,"activeCount":8},[],{"trials":2748,"activeCount":8},[2749],{"nctId":2750,"briefTitle":2751,"status":57,"phases":2752,"primaryCompletion":1352,"completion":1352,"start":147,"enrollment":2753,"conditions":2754,"interventions":2755},"NCT01557777","Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)",[37],17,[1456],[2741],{"trials":2757,"activeCount":8},[],{"trials":2759,"activeCount":8},[],{"trials":2761,"activeCount":8},[],{"intervention":2763,"totalTrials":229,"cells":2764},"Atrasentan low dose group",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2766,"activeCount":8},[],{"trials":2768,"activeCount":8},[],{"trials":2770,"activeCount":8},[2771],{"nctId":2772,"briefTitle":2773,"status":57,"phases":2774,"primaryCompletion":2040,"completion":2040,"start":796,"enrollment":2775,"conditions":2776,"interventions":2777},"NCT01424319","Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan",[37],58,[32,1930],[2763,2778,2779],"Atrasentan high dose group","Atrasentan placebo group",{"trials":2781,"activeCount":8},[],{"trials":2783,"activeCount":8},[],{"trials":2785,"activeCount":8},[],{"intervention":2778,"totalTrials":229,"cells":2787},{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2789,"activeCount":8},[],{"trials":2791,"activeCount":8},[],{"trials":2793,"activeCount":8},[2794],{"nctId":2772,"briefTitle":2773,"status":57,"phases":2795,"primaryCompletion":2040,"completion":2040,"start":796,"enrollment":2775,"conditions":2796,"interventions":2797},[37],[32,1930],[2763,2778,2779],{"trials":2799,"activeCount":8},[],{"trials":2801,"activeCount":8},[],{"trials":2803,"activeCount":8},[],{"intervention":2779,"totalTrials":229,"cells":2805},{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2807,"activeCount":8},[],{"trials":2809,"activeCount":8},[],{"trials":2811,"activeCount":8},[2812],{"nctId":2772,"briefTitle":2773,"status":57,"phases":2813,"primaryCompletion":2040,"completion":2040,"start":796,"enrollment":2775,"conditions":2814,"interventions":2815},[37],[32,1930],[2763,2778,2779],{"trials":2817,"activeCount":8},[],{"trials":2819,"activeCount":8},[],{"trials":2821,"activeCount":8},[],{"intervention":2823,"totalTrials":229,"cells":2824},"ABT-450\u002Fritonavir, ABT-267",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2826,"activeCount":8},[],{"trials":2828,"activeCount":8},[],{"trials":2830,"activeCount":8},[2831],{"nctId":2832,"briefTitle":2833,"status":57,"phases":2834,"primaryCompletion":2835,"completion":2835,"start":2040,"enrollment":2836,"conditions":2837,"interventions":2838},"NCT01672983","A Study to Evaluate ABT-450 With Ritonavir (ABT-450\u002Fr) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection",[37],"2014-05",110,[23],[2823],{"trials":2840,"activeCount":8},[],{"trials":2842,"activeCount":8},[],{"trials":2844,"activeCount":8},[],{"intervention":635,"totalTrials":229,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":8},[],{"trials":2850,"activeCount":8},[],{"trials":2852,"activeCount":8},[2853],{"nctId":625,"briefTitle":626,"status":57,"phases":2854,"primaryCompletion":389,"completion":628,"start":629,"enrollment":630,"conditions":2855,"interventions":2856},[37],[632,633],[606,635,636,637],{"trials":2858,"activeCount":8},[],{"trials":2860,"activeCount":8},[],{"trials":2862,"activeCount":8},[],{"intervention":636,"totalTrials":229,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2866,"activeCount":8},[],{"trials":2868,"activeCount":8},[],{"trials":2870,"activeCount":8},[2871],{"nctId":625,"briefTitle":626,"status":57,"phases":2872,"primaryCompletion":389,"completion":628,"start":629,"enrollment":630,"conditions":2873,"interventions":2874},[37],[632,633],[606,635,636,637],{"trials":2876,"activeCount":8},[],{"trials":2878,"activeCount":8},[],{"trials":2880,"activeCount":8},[],{"intervention":637,"totalTrials":229,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2884,"activeCount":8},[],{"trials":2886,"activeCount":8},[],{"trials":2888,"activeCount":8},[2889],{"nctId":625,"briefTitle":626,"status":57,"phases":2890,"primaryCompletion":389,"completion":628,"start":629,"enrollment":630,"conditions":2891,"interventions":2892},[37],[632,633],[606,635,636,637],{"trials":2894,"activeCount":8},[],{"trials":2896,"activeCount":8},[],{"trials":2898,"activeCount":8},[],{"intervention":1794,"totalTrials":229,"cells":2900},{"EARLY_PHASE1":2901,"PHASE1":2903,"PHASE2":2905,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2902,"activeCount":8},[],{"trials":2904,"activeCount":8},[],{"trials":2906,"activeCount":8},[2907],{"nctId":1789,"briefTitle":1790,"status":57,"phases":2908,"primaryCompletion":390,"completion":390,"start":82,"enrollment":160,"conditions":2909,"interventions":2910},[37],[1785],[1771,1794],{"trials":2912,"activeCount":8},[],{"trials":2914,"activeCount":8},[],{"trials":2916,"activeCount":8},[],{"intervention":1907,"totalTrials":229,"cells":2918},{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2920,"activeCount":8},[],{"trials":2922,"activeCount":8},[],{"trials":2924,"activeCount":8},[2925],{"nctId":1899,"briefTitle":1900,"status":57,"phases":2926,"primaryCompletion":1223,"completion":1223,"start":1902,"enrollment":1903,"conditions":2927,"interventions":2928},[37],[1905],[1907,1908],{"trials":2930,"activeCount":8},[],{"trials":2932,"activeCount":8},[],{"trials":2934,"activeCount":8},[],{"intervention":2936,"totalTrials":229,"cells":2937},"0.25 mg Atrasentan QD",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2939,"activeCount":8},[],{"trials":2941,"activeCount":8},[],{"trials":2943,"activeCount":8},[2944],{"nctId":2945,"briefTitle":2946,"status":57,"phases":2947,"primaryCompletion":1511,"completion":498,"start":170,"enrollment":2948,"conditions":2949,"interventions":2950},"NCT00920764","A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors",[37],92,[32,1930],[2936,2951,2952],"0.75 mg Atrasentan QD","1.75 mg Atrasentan QD",{"trials":2954,"activeCount":8},[],{"trials":2956,"activeCount":8},[],{"trials":2958,"activeCount":8},[],{"intervention":2951,"totalTrials":229,"cells":2960},{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2962,"activeCount":8},[],{"trials":2964,"activeCount":8},[],{"trials":2966,"activeCount":8},[2967],{"nctId":2945,"briefTitle":2946,"status":57,"phases":2968,"primaryCompletion":1511,"completion":498,"start":170,"enrollment":2948,"conditions":2969,"interventions":2970},[37],[32,1930],[2936,2951,2952],{"trials":2972,"activeCount":8},[],{"trials":2974,"activeCount":8},[],{"trials":2976,"activeCount":8},[],{"intervention":2952,"totalTrials":229,"cells":2978},{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2980,"activeCount":8},[],{"trials":2982,"activeCount":8},[],{"trials":2984,"activeCount":8},[2985],{"nctId":2945,"briefTitle":2946,"status":57,"phases":2986,"primaryCompletion":1511,"completion":498,"start":170,"enrollment":2948,"conditions":2987,"interventions":2988},[37],[32,1930],[2936,2951,2952],{"trials":2990,"activeCount":8},[],{"trials":2992,"activeCount":8},[],{"trials":2994,"activeCount":8},[],{"intervention":2996,"totalTrials":229,"cells":2997},"New formulation adalimumab",{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3002,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":2999,"activeCount":8},[],{"trials":3001,"activeCount":8},[],{"trials":3003,"activeCount":8},[3004],{"nctId":3005,"briefTitle":3006,"status":57,"phases":3007,"primaryCompletion":415,"completion":415,"start":407,"enrollment":3008,"conditions":3009,"interventions":3010},"NCT01752855","Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab",[37],88,[14],[2996],{"trials":3012,"activeCount":8},[],{"trials":3014,"activeCount":8},[],{"trials":3016,"activeCount":8},[],{"intervention":3018,"totalTrials":607,"cells":3019},"ABT-806",{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3047,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3021,"activeCount":8},[],{"trials":3023,"activeCount":8},[3024,3032,3040],{"nctId":3025,"briefTitle":3026,"status":57,"phases":3027,"primaryCompletion":407,"completion":407,"start":351,"enrollment":3028,"conditions":3029,"interventions":3030},"NCT01472003","An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types",[36],18,[1174],[3018,3031],"ABT-806i",{"nctId":3033,"briefTitle":3034,"status":57,"phases":3035,"primaryCompletion":3036,"completion":3036,"start":351,"enrollment":3037,"conditions":3038,"interventions":3039},"NCT01406119","An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors",[36],"2017-01",14,[1174],[3018],{"nctId":3041,"briefTitle":3042,"status":57,"phases":3043,"primaryCompletion":390,"completion":390,"start":1141,"enrollment":3044,"conditions":3045,"interventions":3046},"NCT01255657","A Study of ABT-806 in Subjects With Advanced Solid Tumor Types",[36],49,[1174],[3018],{"trials":3048,"activeCount":8},[],{"trials":3050,"activeCount":8},[],{"trials":3052,"activeCount":8},[],{"trials":3054,"activeCount":8},[],{"intervention":3056,"totalTrials":193,"cells":3057},"ABT-348",{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3084,"PHASE3":3086,"PHASE4":3088,"NA":3090},{"trials":3059,"activeCount":8},[],{"trials":3061,"activeCount":8},[3062,3071],{"nctId":3063,"briefTitle":3064,"status":57,"phases":3065,"primaryCompletion":350,"completion":350,"start":297,"enrollment":3066,"conditions":3067,"interventions":3068},"NCT01110486","ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors",[36],102,[1174],[3056,3069,3070,3056,3056],"ABT-348 and carboplatin","ABT-348 and docetaxel",{"nctId":3072,"briefTitle":3073,"status":57,"phases":3074,"primaryCompletion":332,"completion":332,"start":1511,"enrollment":3075,"conditions":3076,"interventions":3082},"NCT01110473","ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies",[36],52,[3077,3078,3079,3080,3081],"Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","B-cell Chronic Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Myelodysplasia",[3056,3056,3083,3056],"ABT-348 and azacitidine",{"trials":3085,"activeCount":8},[],{"trials":3087,"activeCount":8},[],{"trials":3089,"activeCount":8},[],{"trials":3091,"activeCount":8},[],{"intervention":1467,"totalTrials":193,"cells":3093},{"EARLY_PHASE1":3094,"PHASE1":3096,"PHASE2":3114,"PHASE3":3116,"PHASE4":3118,"NA":3120},{"trials":3095,"activeCount":8},[],{"trials":3097,"activeCount":8},[3098,3102],{"nctId":1461,"briefTitle":1462,"status":57,"phases":3099,"primaryCompletion":332,"completion":332,"start":1142,"enrollment":1464,"conditions":3100,"interventions":3101},[36],[1354],[1437,1467,1468,1468],{"nctId":3103,"briefTitle":3104,"status":57,"phases":3105,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":298,"conditions":3108,"interventions":3109},"NCT01472016","Study of ABT-700 in Subjects With Advanced Solid Tumors",[36],"2017-04-27","2011-10-06",[1174],[3110,3111,3112,3113,1467,3110],"ABT-700","docetaxel","FOLFIRI","cetuximab",{"trials":3115,"activeCount":8},[],{"trials":3117,"activeCount":8},[],{"trials":3119,"activeCount":8},[],{"trials":3121,"activeCount":8},[],{"intervention":3031,"totalTrials":229,"cells":3123},{"EARLY_PHASE1":3124,"PHASE1":3126,"PHASE2":3132,"PHASE3":3134,"PHASE4":3136,"NA":3138},{"trials":3125,"activeCount":8},[],{"trials":3127,"activeCount":8},[3128],{"nctId":3025,"briefTitle":3026,"status":57,"phases":3129,"primaryCompletion":407,"completion":407,"start":351,"enrollment":3028,"conditions":3130,"interventions":3131},[36],[1174],[3018,3031],{"trials":3133,"activeCount":8},[],{"trials":3135,"activeCount":8},[],{"trials":3137,"activeCount":8},[],{"trials":3139,"activeCount":8},[],{"intervention":3141,"totalTrials":229,"cells":3142},"ABT-494",{"EARLY_PHASE1":3143,"PHASE1":3145,"PHASE2":3155,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3144,"activeCount":8},[],{"trials":3146,"activeCount":8},[3147],{"nctId":3148,"briefTitle":3149,"status":57,"phases":3150,"primaryCompletion":59,"completion":59,"start":390,"enrollment":3151,"conditions":3152,"interventions":3153},"NCT01741493","A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494",[36],67,[14],[3141,3154],"Tofacitinib",{"trials":3156,"activeCount":8},[],{"trials":3158,"activeCount":8},[],{"trials":3160,"activeCount":8},[],{"trials":3162,"activeCount":8},[],{"intervention":3154,"totalTrials":229,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3173,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3166,"activeCount":8},[],{"trials":3168,"activeCount":8},[3169],{"nctId":3148,"briefTitle":3149,"status":57,"phases":3170,"primaryCompletion":59,"completion":59,"start":390,"enrollment":3151,"conditions":3171,"interventions":3172},[36],[14],[3141,3154],{"trials":3174,"activeCount":8},[],{"trials":3176,"activeCount":8},[],{"trials":3178,"activeCount":8},[],{"trials":3180,"activeCount":8},[],{"intervention":3182,"totalTrials":229,"cells":3183},"ABT-414",{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3197,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3185,"activeCount":8},[],{"trials":3187,"activeCount":8},[3188],{"nctId":3189,"briefTitle":3190,"status":57,"phases":3191,"primaryCompletion":3192,"completion":3192,"start":169,"enrollment":3193,"conditions":3194,"interventions":3196},"NCT01741727","A Study of ABT-414 in Subjects With Solid Tumors",[36],"2015-11",57,[3195],"Squamous Cell Tumors",[3182],{"trials":3198,"activeCount":8},[],{"trials":3200,"activeCount":8},[],{"trials":3202,"activeCount":8},[],{"trials":3204,"activeCount":8},[],{"intervention":1450,"totalTrials":229,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3215,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3208,"activeCount":8},[],{"trials":3210,"activeCount":8},[3211],{"nctId":1444,"briefTitle":1445,"status":57,"phases":3212,"primaryCompletion":1447,"completion":1447,"start":1142,"enrollment":334,"conditions":3213,"interventions":3214},[36],[1354],[1437,1450],{"trials":3216,"activeCount":8},[],{"trials":3218,"activeCount":8},[],{"trials":3220,"activeCount":8},[],{"trials":3222,"activeCount":8},[],{"intervention":1458,"totalTrials":229,"cells":3224},{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3233,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3226,"activeCount":8},[],{"trials":3228,"activeCount":8},[3229],{"nctId":1452,"briefTitle":1453,"status":57,"phases":3230,"primaryCompletion":269,"completion":269,"start":71,"enrollment":285,"conditions":3231,"interventions":3232},[36],[1456],[1437,1458,1459],{"trials":3234,"activeCount":8},[],{"trials":3236,"activeCount":8},[],{"trials":3238,"activeCount":8},[],{"trials":3240,"activeCount":8},[],{"intervention":1459,"totalTrials":229,"cells":3242},{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3251,"PHASE3":3253,"PHASE4":3255,"NA":3257},{"trials":3244,"activeCount":8},[],{"trials":3246,"activeCount":8},[3247],{"nctId":1452,"briefTitle":1453,"status":57,"phases":3248,"primaryCompletion":269,"completion":269,"start":71,"enrollment":285,"conditions":3249,"interventions":3250},[36],[1456],[1437,1458,1459],{"trials":3252,"activeCount":8},[],{"trials":3254,"activeCount":8},[],{"trials":3256,"activeCount":8},[],{"trials":3258,"activeCount":8},[],{"intervention":3260,"totalTrials":229,"cells":3261},"ABT-981",{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3263,"activeCount":8},[],{"trials":3265,"activeCount":8},[3266],{"nctId":3267,"briefTitle":3268,"status":57,"phases":3269,"primaryCompletion":415,"completion":415,"start":94,"enrollment":766,"conditions":3270,"interventions":3272},"NCT01668511","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee",[36],[3271],"Osteoarthritis",[3260],{"trials":3274,"activeCount":8},[],{"trials":3276,"activeCount":8},[],{"trials":3278,"activeCount":8},[],{"trials":3280,"activeCount":8},[],{"intervention":3282,"totalTrials":229,"cells":3283},"ABT-767",{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3300,"PHASE3":3302,"PHASE4":3304,"NA":3306},{"trials":3285,"activeCount":8},[],{"trials":3287,"activeCount":8},[3288],{"nctId":3289,"briefTitle":3290,"status":57,"phases":3291,"primaryCompletion":3292,"completion":3292,"start":3293,"enrollment":3294,"conditions":3295,"interventions":3299},"NCT01339650","Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[36],"2017-11-30","2011-05-06",93,[3296,3297,3298],"Fallopian Tube","Primary Peritoneal Cancer","Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian",[3282],{"trials":3301,"activeCount":8},[],{"trials":3303,"activeCount":8},[],{"trials":3305,"activeCount":8},[],{"trials":3307,"activeCount":8},[],{"intervention":3069,"totalTrials":229,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3318,"PHASE3":3320,"PHASE4":3322,"NA":3324},{"trials":3311,"activeCount":8},[],{"trials":3313,"activeCount":8},[3314],{"nctId":3063,"briefTitle":3064,"status":57,"phases":3315,"primaryCompletion":350,"completion":350,"start":297,"enrollment":3066,"conditions":3316,"interventions":3317},[36],[1174],[3056,3069,3070,3056,3056],{"trials":3319,"activeCount":8},[],{"trials":3321,"activeCount":8},[],{"trials":3323,"activeCount":8},[],{"trials":3325,"activeCount":8},[],{"intervention":3070,"totalTrials":229,"cells":3327},{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3336,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3329,"activeCount":8},[],{"trials":3331,"activeCount":8},[3332],{"nctId":3063,"briefTitle":3064,"status":57,"phases":3333,"primaryCompletion":350,"completion":350,"start":297,"enrollment":3066,"conditions":3334,"interventions":3335},[36],[1174],[3056,3069,3070,3056,3056],{"trials":3337,"activeCount":8},[],{"trials":3339,"activeCount":8},[],{"trials":3341,"activeCount":8},[],{"trials":3343,"activeCount":8},[],{"intervention":3345,"totalTrials":229,"cells":3346},"ABT-199",{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3360,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3348,"activeCount":8},[],{"trials":3350,"activeCount":8},[3351],{"nctId":3352,"briefTitle":3353,"status":57,"phases":3354,"primaryCompletion":3355,"completion":3355,"start":390,"enrollment":3356,"conditions":3357,"interventions":3359},"NCT01686555","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)",[36],"2015-06",97,[3358],"Lupus Erythematosus",[3345],{"trials":3361,"activeCount":8},[],{"trials":3363,"activeCount":8},[],{"trials":3365,"activeCount":8},[],{"trials":3367,"activeCount":8},[],{"intervention":3083,"totalTrials":229,"cells":3369},{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3378,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3371,"activeCount":8},[],{"trials":3373,"activeCount":8},[3374],{"nctId":3072,"briefTitle":3073,"status":57,"phases":3375,"primaryCompletion":332,"completion":332,"start":1511,"enrollment":3075,"conditions":3376,"interventions":3377},[36],[3077,3078,3079,3080,3081],[3056,3056,3083,3056],{"trials":3379,"activeCount":8},[],{"trials":3381,"activeCount":8},[],{"trials":3383,"activeCount":8},[],{"trials":3385,"activeCount":8},[],{"intervention":1336,"totalTrials":229,"cells":3387},{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3396,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3389,"activeCount":8},[],{"trials":3391,"activeCount":8},[3392],{"nctId":1329,"briefTitle":1330,"status":57,"phases":3393,"primaryCompletion":1323,"completion":1323,"start":147,"enrollment":285,"conditions":3394,"interventions":3395},[36],[1333],[1335,1336],{"trials":3397,"activeCount":8},[],{"trials":3399,"activeCount":8},[],{"trials":3401,"activeCount":8},[],{"trials":3403,"activeCount":8},[],{"intervention":1468,"totalTrials":229,"cells":3405},{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3414,"PHASE3":3416,"PHASE4":3418,"NA":3420},{"trials":3407,"activeCount":8},[],{"trials":3409,"activeCount":8},[3410],{"nctId":1461,"briefTitle":1462,"status":57,"phases":3411,"primaryCompletion":332,"completion":332,"start":1142,"enrollment":1464,"conditions":3412,"interventions":3413},[36],[1354],[1437,1467,1468,1468],{"trials":3415,"activeCount":8},[],{"trials":3417,"activeCount":8},[],{"trials":3419,"activeCount":8},[],{"trials":3421,"activeCount":8},[],{"intervention":3110,"totalTrials":229,"cells":3423},{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3425,"activeCount":8},[],{"trials":3427,"activeCount":8},[3428],{"nctId":3103,"briefTitle":3104,"status":57,"phases":3429,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":298,"conditions":3430,"interventions":3431},[36],[1174],[3110,3111,3112,3113,1467,3110],{"trials":3433,"activeCount":8},[],{"trials":3435,"activeCount":8},[],{"trials":3437,"activeCount":8},[],{"trials":3439,"activeCount":8},[],{"intervention":3111,"totalTrials":229,"cells":3441},{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3450,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3443,"activeCount":8},[],{"trials":3445,"activeCount":8},[3446],{"nctId":3103,"briefTitle":3104,"status":57,"phases":3447,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":298,"conditions":3448,"interventions":3449},[36],[1174],[3110,3111,3112,3113,1467,3110],{"trials":3451,"activeCount":8},[],{"trials":3453,"activeCount":8},[],{"trials":3455,"activeCount":8},[],{"trials":3457,"activeCount":8},[],{"intervention":3112,"totalTrials":229,"cells":3459},{"EARLY_PHASE1":3460,"PHASE1":3462,"PHASE2":3468,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3461,"activeCount":8},[],{"trials":3463,"activeCount":8},[3464],{"nctId":3103,"briefTitle":3104,"status":57,"phases":3465,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":298,"conditions":3466,"interventions":3467},[36],[1174],[3110,3111,3112,3113,1467,3110],{"trials":3469,"activeCount":8},[],{"trials":3471,"activeCount":8},[],{"trials":3473,"activeCount":8},[],{"trials":3475,"activeCount":8},[],{"intervention":3113,"totalTrials":229,"cells":3477},{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3486,"PHASE3":3488,"PHASE4":3490,"NA":3492},{"trials":3479,"activeCount":8},[],{"trials":3481,"activeCount":8},[3482],{"nctId":3103,"briefTitle":3104,"status":57,"phases":3483,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":298,"conditions":3484,"interventions":3485},[36],[1174],[3110,3111,3112,3113,1467,3110],{"trials":3487,"activeCount":8},[],{"trials":3489,"activeCount":8},[],{"trials":3491,"activeCount":8},[],{"trials":3493,"activeCount":8},[],{"intervention":66,"totalTrials":797,"cells":3495},{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3515,"PHASE4":3637,"NA":3664},{"trials":3497,"activeCount":8},[],{"trials":3499,"activeCount":8},[],{"trials":3501,"activeCount":8},[3502,3508],{"nctId":3503,"briefTitle":3504,"status":57,"phases":3505,"primaryCompletion":390,"completion":390,"start":296,"enrollment":271,"conditions":3506,"interventions":3507},"NCT01502423","A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab",[37],[14],[66],{"nctId":3509,"briefTitle":3510,"status":57,"phases":3511,"primaryCompletion":390,"completion":390,"start":1100,"enrollment":3512,"conditions":3513,"interventions":3514},"NCT01561313","Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.",[37],64,[14],[66],{"trials":3516,"activeCount":8},[3517,3524,3533,3541,3548,3556,3565,3569,3577,3583,3587,3594,3602,3610,3614,3618,3622,3626,3630],{"nctId":3518,"briefTitle":3519,"status":57,"phases":3520,"primaryCompletion":379,"completion":379,"start":341,"enrollment":1364,"conditions":3521,"interventions":3523},"NCT01468207","Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa",[38],[3522],"Hidradenitis Suppurativa (HS)",[99],{"nctId":3525,"briefTitle":3526,"status":57,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":1109,"enrollment":3529,"conditions":3530,"interventions":3532},"NCT01550965","A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting",[38],"2015-04",463,[3531],"Ulcerative Colitis",[66],{"nctId":3534,"briefTitle":3535,"status":57,"phases":3536,"primaryCompletion":3537,"completion":3537,"start":3538,"enrollment":1732,"conditions":3539,"interventions":3540},"NCT00686374","Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806",[38],"2017-04-04","2008-05-01",[30],[66],{"nctId":3542,"briefTitle":3543,"status":57,"phases":3544,"primaryCompletion":59,"completion":59,"start":313,"enrollment":3545,"conditions":3546,"interventions":3547},"NCT01646073","Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis",[38],425,[64],[66],{"nctId":3549,"briefTitle":3550,"status":57,"phases":3551,"primaryCompletion":796,"completion":2835,"start":3552,"enrollment":2311,"conditions":3553,"interventions":3555},"NCT01064856","Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)",[38],"2010-02",[3554],"Peripheral Spondyloarthritis",[66],{"nctId":3557,"briefTitle":3558,"status":57,"phases":3559,"primaryCompletion":3560,"completion":3560,"start":3561,"enrollment":3562,"conditions":3563,"interventions":3564},"NCT00573794","Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis",[38],"2016-12","2007-11-28",592,[3531],[99],{"nctId":55,"briefTitle":56,"status":57,"phases":3566,"primaryCompletion":59,"completion":60,"start":61,"enrollment":62,"conditions":3567,"interventions":3568},[38],[64],[66,43],{"nctId":3570,"briefTitle":3571,"status":57,"phases":3572,"primaryCompletion":390,"completion":158,"start":117,"enrollment":3573,"conditions":3574,"interventions":3576},"NCT01166282","A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis",[38],46,[3575],"Enthesitis Related Arthritis (ERA)",[99],{"nctId":3578,"briefTitle":3579,"status":57,"phases":3580,"primaryCompletion":370,"completion":971,"start":1171,"enrollment":1143,"conditions":3581,"interventions":3582},"NCT00853099","A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis",[38],[3531],[99],{"nctId":667,"briefTitle":668,"status":57,"phases":3584,"primaryCompletion":670,"completion":406,"start":671,"enrollment":672,"conditions":3585,"interventions":3586},[38],[674],[66,656],{"nctId":3588,"briefTitle":3589,"status":57,"phases":3590,"primaryCompletion":159,"completion":159,"start":361,"enrollment":285,"conditions":3591,"interventions":3593},"NCT00775437","Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use",[38],[3592],"Juvenile Idiopathic Arthritis",[66],{"nctId":3595,"briefTitle":3596,"status":57,"phases":3597,"primaryCompletion":1341,"completion":1341,"start":82,"enrollment":3598,"conditions":3599,"interventions":3601},"NCT01635764","Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa",[38],508,[3600],"Hidradenitis Suppurativa",[99],{"nctId":3603,"briefTitle":3604,"status":57,"phases":3605,"primaryCompletion":1100,"completion":332,"start":95,"enrollment":3606,"conditions":3607,"interventions":3609},"NCT01243671","A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease",[38],20,[3608],"Intestinal Behçet's Disease",[66],{"nctId":677,"briefTitle":678,"status":57,"phases":3611,"primaryCompletion":680,"completion":681,"start":682,"enrollment":683,"conditions":3612,"interventions":3613},[38],[30],[66,656,686],{"nctId":968,"briefTitle":969,"status":57,"phases":3615,"primaryCompletion":342,"completion":971,"start":360,"enrollment":972,"conditions":3616,"interventions":3617},[38],[974],[66,957],{"nctId":78,"briefTitle":79,"status":57,"phases":3619,"primaryCompletion":81,"completion":82,"start":83,"enrollment":84,"conditions":3620,"interventions":3621},[38],[86],[66,43,88,89],{"nctId":688,"briefTitle":689,"status":57,"phases":3623,"primaryCompletion":691,"completion":691,"start":671,"enrollment":692,"conditions":3624,"interventions":3625},[38],[674],[66,656],{"nctId":91,"briefTitle":92,"status":57,"phases":3627,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":3628,"interventions":3629},[38],[86],[99,100],{"nctId":3631,"briefTitle":3632,"status":57,"phases":3633,"primaryCompletion":1108,"completion":1108,"start":341,"enrollment":3634,"conditions":3635,"interventions":3636},"NCT01468233","Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa",[38],326,[3522],[99],{"trials":3638,"activeCount":8},[3639,3643,3649,3656,3660],{"nctId":104,"briefTitle":105,"status":57,"phases":3640,"primaryCompletion":94,"completion":94,"start":107,"enrollment":108,"conditions":3641,"interventions":3642},[39],[110],[99,100],{"nctId":3644,"briefTitle":3645,"status":57,"phases":3646,"primaryCompletion":350,"completion":350,"start":1109,"enrollment":343,"conditions":3647,"interventions":3648},"NCT01644396","An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation",[39],[536],[66],{"nctId":3650,"briefTitle":3651,"status":57,"phases":3652,"primaryCompletion":333,"completion":333,"start":95,"enrollment":3653,"conditions":3654,"interventions":3655},"NCT01265823","Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis",[39],150,[20],[66],{"nctId":113,"briefTitle":114,"status":57,"phases":3657,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":3658,"interventions":3659},[39],[14],[66,43],{"nctId":122,"briefTitle":123,"status":57,"phases":3661,"primaryCompletion":125,"completion":125,"start":117,"enrollment":126,"conditions":3662,"interventions":3663},[39],[14],[99,43],{"trials":3665,"activeCount":8},[3666,3675],{"nctId":3667,"briefTitle":3668,"status":57,"phases":3669,"primaryCompletion":3670,"completion":3670,"start":3671,"enrollment":3672,"conditions":3673,"interventions":3674},"NCT01387815","Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis",[],"2018-06-29","2011-08-16",662,[20],[66],{"nctId":3676,"briefTitle":3677,"status":57,"phases":3678,"primaryCompletion":3679,"completion":3679,"start":3680,"enrollment":1535,"conditions":3681,"interventions":3682},"NCT01736189","Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice",[],"2018-04-16","2012-10-11",[14],[66],{"intervention":824,"totalTrials":1161,"cells":3684},{"EARLY_PHASE1":3685,"PHASE1":3687,"PHASE2":3689,"PHASE3":3691,"PHASE4":3722,"NA":3728},{"trials":3686,"activeCount":8},[],{"trials":3688,"activeCount":8},[],{"trials":3690,"activeCount":8},[],{"trials":3692,"activeCount":8},[3693,3697,3705,3713],{"nctId":817,"briefTitle":818,"status":57,"phases":3694,"primaryCompletion":82,"completion":82,"start":370,"enrollment":820,"conditions":3695,"interventions":3696},[38],[17,822],[824,806,825,826],{"nctId":3698,"briefTitle":3699,"status":57,"phases":3700,"primaryCompletion":3528,"completion":3528,"start":351,"enrollment":3701,"conditions":3702,"interventions":3704},"NCT01382212","A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",[38],13,[3703,17],"End-Stage Renal Disease",[824],{"nctId":3706,"briefTitle":3707,"status":57,"phases":3708,"primaryCompletion":117,"completion":1100,"start":533,"enrollment":3709,"conditions":3710,"interventions":3712},"NCT00497146","The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3\u002F4",[38],227,[32,3711],"Left Ventricular Hypertrophy",[824],{"nctId":3714,"briefTitle":3715,"status":57,"phases":3716,"primaryCompletion":2835,"completion":3717,"start":3552,"enrollment":3718,"conditions":3719,"interventions":3721},"NCT01020487","Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)",[38],"2014-12",47,[3720],"Chronic Kidney Disease Stage 3 and 4",[252],{"trials":3723,"activeCount":8},[3724],{"nctId":242,"briefTitle":243,"status":57,"phases":3725,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":3726,"interventions":3727},[39],[249,250],[252,228],{"trials":3729,"activeCount":8},[3730],{"nctId":3731,"briefTitle":3732,"status":1089,"phases":3733,"primaryCompletion":1109,"completion":1109,"start":3734,"enrollment":271,"conditions":3735,"interventions":3736},"NCT01134315","Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice",[],"2010-06",[17,3703],[252,3737],"Calcitriol",{"intervention":3737,"totalTrials":229,"cells":3739},{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3744,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3741,"activeCount":8},[],{"trials":3743,"activeCount":8},[],{"trials":3745,"activeCount":8},[],{"trials":3747,"activeCount":8},[],{"trials":3749,"activeCount":8},[],{"trials":3751,"activeCount":8},[3752],{"nctId":3731,"briefTitle":3732,"status":1089,"phases":3753,"primaryCompletion":1109,"completion":1109,"start":3734,"enrollment":271,"conditions":3754,"interventions":3755},[],[17,3703],[252,3737],{"intervention":3757,"totalTrials":229,"cells":3758},"Lopinavir \u002F ritonavir",{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3765,"PHASE4":3767,"NA":3769},{"trials":3760,"activeCount":8},[],{"trials":3762,"activeCount":8},[],{"trials":3764,"activeCount":8},[],{"trials":3766,"activeCount":8},[],{"trials":3768,"activeCount":8},[],{"trials":3770,"activeCount":8},[3771],{"nctId":3772,"briefTitle":3773,"status":57,"phases":3774,"primaryCompletion":3775,"completion":3775,"start":147,"enrollment":3776,"conditions":3777,"interventions":3779},"NCT01662336","Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program",[],"2016-06",173,[3778],"Human Immunodeficiency Virus Infection",[3757]]